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ABSTRACT 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University 
Thomas Harris Inge 
Virginia Commonwealth University 
Advisor: Harry D. Bear, M.D., Ph.D. 
Transforming growth factor-� 1 (TGF�) is a peptide cytokine implicated in 
control of growth, adhesion, and differentiation of cells in numerous tissues. TGF� 
has potent inhibitory effects on many lymphocyte responses; we also found that TGF� 
could inhibit in vitro generation of tumor-specific CTL. Suppression was largely 
reversed with exogenous IL-2. Proliferation of memory-stage CTL clones was also 
inhibited by TGF�, while the upregulation of cytotoxicity was not inhibited by TGF�. 
These studies suggested that TGF� limited anti-tumor CTL responses via both an 
indirect effect on IL-2 production, and by a direct effect on proliferation of memory 
CTL. 
In CTLL-2 cells, TGF� inhibited IL-2-dependent DNA synthesis and cell 
Xli 
growth as early as 24h after addition. TGFp inhibited IL-2-dependent surface IL-2Ra 
expression 24h after treatment, while cells remained 1 0 0% IL-2R+ up to 4Sh after 
treatment. TGFp inhibited c-myc mRNA expression as early as 1 h after treatment, 
suggesting that TGFp may inhibit T cell growth by either altering signal transduction 
through the IL-2R, or by otherwise inhibiting early gene expression events triggered by 
IL-2 binding. 
TGFp treatment also resulted in morphologic changes and increased adherence 
in 5 0% of CTLL-2 cells. Adherence required the presence of fetal calf serum and 
could be largely blocked by RGDS peptides. Under these conditions, de novo surface 
expression of CDSa and CDSP was observed and these cells rapidly accumulated 
mRNA encoding both CDSa and P chains, to a level 4-fold greater than control. 
Treatment of CD4-CDS- thymocytes with IL-2 + TGFp similarly induced high 
levels of de novo CDSa expression on one-third of cells, while few thymocytes treated 
with IL-2 alone became CDSa+. CDS expression in mature, peripheral CDS+ cells was 
not influenced by TGFp. These data suggest that TGFp has both positive and negative 
regulatory effects on the expression of molecules important for T lymphocyte growth, 
differentiation and function, and TGFp may be a physiologically important cytokine 
for initial expression of CDS in the thymus. 
Introduction 
Mammalian organisms are composed of complex networks of cells that, allied 
as tissues, work in concert to perform intricate tasks that are, in most cases, poorly 
understood. For any group of individuals to unite and advance their cause, a highly 
structured plan must exist and be rigorously followed. We have learned that the 
nucleic genome is such a plan. The genes (and the mechanisms which organize and 
regulate their expression) provide cells with the raw materials to accomplish the plan. 
Fundamental biological tenets have held that the expression of our genes is 
conservatively gaurded in a cell-type specific manner and restrained in order to lend 
precise identity to particular cells. In this way, neurons and hepatocytes need not 
concern themselves with acid secretion, any more than pancreatic acinar cells should 
be troubled to construct globin molecules. This sounds very logical, and as a 
paradigm to understand general aspects of biology, is quite sufficient. However, flaws 
in this model have emerged during the study of cell-cell communication, because so 
many different cell types express identical receptors for, and respond to, the same 
hormonal factors. This is especially true when considering the factors produced by 
cells of the immune system. 
Over several millennia our immune system has evolved into an militant, and 
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almost intelligent force to accomplish an assortment of tasks, including the eradication 
of invading microorganisms and viruses, and repression of neoplastic upheavals from 
within. The iinmune system is endowed with highly evolved mechanisms of 
intercellular communication--an attribute which provides important and ingenious 
humoral links in the chain of command. This communication is made possible by the 
production of various cytokines, which are small glycoproteins that are analogous to 
hormones of the endocrine system. These glycoproteins act in an antigen-nonspecific 
manner to send signals from one cell to another over short distances. Thus, many of 
the cytokines elaborated by leukocytes in the immune system were dubbed 
"interleukins," since they functioned between leukocytes. However, since the 
identification of numerous interleukins, it has become evident that the expression of 
receptors for most of these factors is not restricted to the surface of leukocytes, but 
receptors for interleukins exist on many different somatic cells; this fact makes evident 
the inaccuracy in the term "interleukin" (and thus the preference of the general term 
cytokine) and exposes the most flaws in the dogma of cell specific gene expression. A 
few examples will illustrate this point. Interleukin-l (lL-I) is produced by antigen 
presenting cells and macrophages of the reticuloendothelial system but has important 
actions on cellular proliferation, prostaglandin and protein synthesis, and metabolism in 
general via interaction with IL-I receptors that are expressed in cells of the lymphoid 
system, nervous system, liver, bone, synovium, muscle and connective tissue, 
endothelium, and epithelium. Other cytokines for which non-tissue-specific receptor 
expression is seen include tumor necrosis factor-a (TNFa), the interferons, other 
interleukins, and the colony stimulating factors. It has also been noted that cytokine 
receptors are organized into families, based on structural similarities. Granulocyte-
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macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3), and interleukin-
5 (IL-5) have multiple unique and common effects on various cells of the 
hematopoeitic system, but also regulate inflammation, cell adherence, and allergic 
reactions in part because these cytokines share a common receptor � subunit, capable 
of crossreacting with these different cytokines (Lopez et aI., 1992). Perhaps the best 
example of this "one cytokine, multiple effects" concept is demonstrated by 
transforming growth factor-p (TGFP). Some have likened this factor to a "switch," 
since the effects of TGFp on cells can be stimulatory or inhibitory, depending on the 
particular context (Sporn and Roberts, 199 0). Factors that have been shown to govern 
this context include the physiologic state of the target cell (activated or dormant), the 
other cytokines that the target cells is exposed to, as well as the nature of the TGFp 
receptors that are being expressed by the target cell. Thus, numerous examples attest 
to the fact cytokines act broadly on many distinct tissue types, and can therefore have 
many different effects within the body. A paradox arises when we consider that 
although the expression of cytokine receptor genes is not restricted to particular tissue­
types, the response to engagement of a cytokine receptor is often quite specific and 
restricted to a particular tissue or context. Therefore, the challenge now is the 
elucidation of cytoplasmic biochemical signalling pathways that receptors are plugged 
into in any particular cell type. The response to the interaction of any particular 
cytokine with its cell surface receptor then depends in large part on the downstream 
elements which are triggered by the receptor in the particular target cell, as well as the 
quantities and particular combination of other cytokines in the extracellular milieu. 
The work that follows will illustrate a number of interesting new roles of 
regulating T lymphocyte physiology that can be assigned to TGF�. 
Literature Review 
Transforming growth factors-(3 
Transfonning growth factors-p (TGFps) refers to a group of closely related 
peptide factors that are involved in the regulation of cellular proliferation, differenti­
ation, and adhesion. TGFp was originally described as a product of virally trans­
fonned cell lines capable of causing reversible anchorage-independent growth 
("transfonnationtl) of nonnal rat kidney fibroblasts (Ellingsworth, 199 0; Roberts et al., 
198 1). However, since these original observations, the vast majority of studies have 
shown that the effect of TGFp on cell proliferation is inhibitory, revealing that TGFp 
is in most cases, a misnomer. There are 3 distinct genes coding for 25kD 
heterodimeric TGFp peptides that show highly conserved primary sequences. Mature 
TGFp consists of two peptide subunits of 112 amino acids each, bonded together via 
disulfide bridges, a structure which is necessary for TGFWs biologic activity. TGFp is 
found in highest quantities in bone and platelets (>4 0 0ng/g) but is also produced by a 
variety of activated cells including macrophages, platelets, tumor cells, neutrophils, and 
activated T helper lymphocytes (Kehrl et al., 1986b; Grotendorst et al., 1989). Amino 
acid sequence analysis demonstrates that this rather ubiquitous cytokine has been 
highly conserved evolutionarily with only one amino acid difference in primary 
4 
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sequence between mouse and man and only a two percent difference between man and 
chicken. From the above information it is not difficult to imagine that this peptide 
might have multiple functions and effects on different tissues; indeed the thousands of 
manuscripts related to TGF� that have been published over the last decade support this 
premise. 
TGF� is a highly potent immunomodulatory peptide for T lymphocyte respons­
es and has antiproliferative effects at doses as low as 1 ng/ml (Stoeck et ai., 1989a; 
Wahl et ai., 1988; Ellingsworth et ai., 1988; Stoeck et ai., 1989b; Kehrl et ai., 1986b). 
TGF� has been shown to inhibit the proliferation of hematopoietic progenitors (Keller 
et ai., 199 0; Cashman et ai., 199 0), as well as the activation and proliferation of CTL 
(Ranges et ai., 1987; Fontana et ai., 1989; Shalaby and Amman, 1988; Wallick et ai., 
199 0; Tada et ai., 1991), Iymphokine activated killer cells (Kasid et ai., 1988; Kuppner 
et ai., 1988; Mule et ai., 1988; Hirte and Clark, 1991), and B lymphocytes (Quere and 
Thorbecke, 199 0; Shalaby and Amman, 1988; Coffman et ai., 1989). It has also been 
shown recently that TGF� inhibits the appearance of perforin mRNA in T cells 
stimulated with anti-CD3 mAb and IL-2 (Smyth et ai., 1991). Many studies have 
examined mitogenic or antigenic responses of heterogeneous populations of naive lym­
phocytes (Kono et ai., 199 0; Stoeck et ai., 1989b; Quere and Thorbecke, 199 0; 
Fontana et ai., 1989) in which the inhibition of T cell activities may occur at a number 
of points. The suppressive effects of TGF� on responsiveness to IL-l (Wahl et ai., 
1988; Morris et ai., 1989) and IL-4 (Ruegemer et ai., 199 0) have been well 
documented and may account indirectly for the anti proliferative effects of TGF� on 
some T cell populations. There is mixed opinion as to the effect of TGF� on IL-2 
production, with some reports suggesting suppression (Van Norstrand et ai., 199 0) and 
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some no effect (Wahl et al., 1988). 
It has been shown that TGFp has no effect on the rise in intracellular Ca++ seen 
immediately following T lymphocyte stimulation with anti-CD3 (Stoeck et aI., 1989b) 
or Concanavalin-A (Con-A) (Morris et al., 1989). However, c-myc expression is 
inhibited by TGFp in some cell lines (Ruegemer et al., 199 0) but not in nonnal 
peripheral T cells (Morris et al., 1989). The effect of TGFp on IL-2R expression is 
also controversial. Kehrl, investigating the effect of TGFp on mitogenic responses of 
human tonsillar T cells, showed a 6 0-8 0% suppression of IL-2-dependent DNA synthe­
sis of ConA activated T cells (Kehrl et aI., 1986b). In this study, TGFp seemed to 
inhibit IL-2-dependent up-regulation of surface IL-2Ra. In experiments done with two 
constitutively activated T cell clones, Ruegemer et al. found that proliferation was 
inhibited in both HT-2 (CD4+) and CT6 (CD8+) cell lines by TGFp, but high affinity 
IL-2R expression was decreased by TGFp only on HT-2 cells (Ruegemer et aI., 199 0). 
Conversely, growth factor dependent IL-2Ra rnRNA levels were unaffected by TGFp 
in HT-2 cells but were decreased by 8 0% in CT6. IL-2Ra expression on the cell 
surface was not altered by TGFp in either of these cell lines. Wahl has shown that the 
proliferative response of peripheral blood mononuclear cells (PBMC) to lectin was 
inhibited by simultaneous administration of TGFp, but that IL-2Ra rnRNA and surface 
levels were not affected (Wahl et aI., 1988). Smyth et al. reported a slight enhance­
ment of surface IL-2Ra expression when CD8+ T cells were cultured in TGFp and 
high dose IL-2 (Smyth et aI., 1991). There are contrasting results regarding the anti­
proliferative effects of TGFp on the widely used IL-2-dependent CTLL-2 T cell line. 
Interestingly, Ellingsworth reported that TGFp did not inhibit proliferation of his 
CTLL-2 line (Ellingsworth et aI., 1988), whereas Stoeck found that TGFp at 1-5ng/ml 
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inhibited CTLL-2 cell cycle progression by 75-85% on day 1; however, surface IL-
2Ra was not decreased in the treated group until d3 (Stoeck et aI., 1989a). Ortaldo et 
al. have recently described the effects of TGFp on human large granular lymphocytes 
in which IL-2Ra levels were decreased but surface expression of the p75 chain of IL-
2R were unchanged (Ortaldo et al., 1991). They reported that TGFp inhibited IL-2 
induced LGL functions mediated by IL-2RP and that the inhibition was at a post­
receptor binding level that appeared to involve regulation of initial signalling events. 
As noted above, most of TGFp's effects on cells of the immune system have 
been inhibitory, leading most authors to refer to TGFp as immunosuppressive. 
However, TGFp stimulates cellular functions in many different tissue types, including 
fibroblasts and osteoblasts. For instance, osteoblast lines responded to TGFp with 
increased alkaline phosphatase activity and collagen synthesis (Mundy and Bonewald, 
1990). With respect to cells of the immune system, studies of murine B cells 
demonstrated that TGFp inhibits proliferation and total immunoglobulin synthesis, 
while increasing both class II expression (Cross and Cambier, 1990) and differentiation 
toward an IgA-producing lineage (Coffman et aI., 1989). The enhancement of both 
class II expression and isotype switching to IgA were accompanied by increases in 
steady state levels of mRNA for these genes (Lebman et aI., 1990a; Lebman et al., 
1990b). 
In summary, TGFp is a product of both nonnal and neoplastic cells and 
probably plays a pennissive role in progression of tumor growth. The mechanism by 
which this effect is accomplished is unknown but may relate to the fact that TGFp 
inhlbig proliferation of antitumor T cells. Finally, TGFp has been described as a 
differentiahontpt0n10tmg "switch" for numerous cell types but as yet, little is known 
8 
about the effects of TGF� on T lymphocyte differentiation. 
Cluster of Differentiation 8 
CD8 is expressed on mature T lymphocytes, NK cells, and the CD8 
glycoprotein has been described as both a T cell accessory molecule and as a 
differentiation antigen (Parnes, 1989). Non MHC-restricted NK cells can express CD8 
as aa homodimers, whereas CD8 that exists on MHC class I-restricted T cells is 
expressed as a� heterodimers. On T cells, CD8� must form heterodimers with CD8a 
in order for surface expression of � chains to occur. Considerable data support the 
hypothesis that CD8 molecules on T lymphocytes act as receptors for non-polymorphic 
determinants of MHC class I molecules on accessory and target cells (Parnes, 1989; 
Meuer et aI., 1982; Rosenstein et aI., 1989; Norment et aI., 1988; Swain, 1981). 
These CD8-class I interactions appear to increase the avidity of T cell-target cell 
contact and also positively influence transmembrane signal transduction in T cells via 
an interaction between the intracytoplasmic domain of CD8 and the protein tyrosine 
kinase p561ck (Gilliland et aI., 1991; Miceli et aI., 1991; Letourneur et aI., 1990). 
Murine CD8 was originally defined by the monoclonal antibodies (mAB)s specific for 
Lyt2 and Lyt3 determinants that reside on the CD8a and CD8� chains respectively. It 
is now known that the CD8a gene can give rise to 2 forms of peptide, designated as a 
or a', that differ only by the absence of the cytoplasmic region in the a' form. The 
gene encoding CD8� is located 5' of the CD8a gene, and these are linked. Both are 
members of the immunoglobulin supergene family and are closely linked to the IgK 
light chain locus on chromosome 6. 
In the thymus, CD8 molecules are first expressed after transient expression of 
IL-2Ra and prior to TCR expression. Later, interaction between class I MHC and 
CD8 appears to play an important role in positive selection of MHC class I-restricted, 
a�TCR+ T cells (Nikolic-Zugic, 1991; Boyd and Hugo, 1991; MacDonald et a!., 
1988). The events or mediators that trigger initial expression of CD8 molecules on T 
lymphocytes are unknown. 
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Two fundamental classes of effector function have been ascribed to CD8+ cells: 
antigen specific cytotoxicity and immunoregulation. We have been actively involved 
in investigating the role of CD8+ T cells as 1) mediators of antitumor cytotoxicity in 
vitro (lnge et a!., 1992a; Tuttle et al., 1992; Hoover et a!., 1990b) and in vivo 
(McKinnon et a!., 1990; Hoover et a!., 1990b) and 2) as suppressors of immune 
responses (Bear, 1986; Bear, 1987; Hoover et a!., 1990a). Although the mechanism of 
T cell mediated immunosuppression is not known, several possibilities exist, including 
secretion of immunoregulatory cytokines or other suppressor factors (Weiner et a!., 
1990; Damle and Engleman, 1990). Another interesting possibility for which there are 
compelling data is that the CD8 peptide itself is important in mediating antigen 
specific immunosuppression (Kaplan et a!., 1989; Hambor et a!., 1988; Hambor et a!., 
1990). 
In summary, although many structural and functional details about CD8 have 
been elucidated, thus far the physiologic signals for induction of CD8 expression have 
not been described and therefore molecular analysis of this process has not been 
possible. Therefore, learning more about the expression of the gene for this peptide 
and its regulation by TGF� will be important for understanding normal differentiation 
of CTL and for understanding thymic ontogeny. 
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Interleukin-2-Dependent T Cell Growth 
"T cell activation" describes all of the events that occur which drive a resting, 
Go phase T lymphocyte into mitosis. These events can be broadly divided into two 
distinctly regulated stages. First is the signalling that is achieved by antigen, other 
mitogens (lectins), or phorbol ester/calcium ionophore (PII) which stimulates the 
movement of a Go cell into G1 of the cell cycle. This action has been termed compe­
tence, to denote one result of these events, namely cellular receptiveness to the T cell 
growth factor, interJeukin-2 (IL-2), manifested physically as IL-2R surface expression. 
Antigen, in association with self MHC molecules (Ag/MHC), is the physiologic stimu­
lus for competence. When a T cell receptor (TCR) encounters and binds a particular 
Ag/MHC complex for which it has high affinity, a number of well characterized 
responses occur within a few minutes, including the generation of reactive 
phosphoinositol species and diacylglycerol, translocation of protein kinase C from 
cytosol to membrane, and an increase in cytosolic free calcium ion ([Ca2+]J Within 
the next few hours, nuclear responses predominate which yield production of mRNA 
coding for various activation associated genes, as well as IL-2 and IL-2 receptor (lL-
2R). The production of high affinity (HA, Kd=lO pM) IL-2R and the interaction of 
IL-2 with these receptors results in the progression phase of T cell activation which is 
manifested by entry of G1 phase cells into mitosis. Thus, the interaction of TCR with 
Ag/MHC determines the specificity of the response and IL-2 regulates the magnitude 
of the response. 
IL-2, a well characterized glycoprotein growth factor, is critical to the 
generation of most immune responses. The presence of IL-2R on a wide variety of 
cells is evidence for the broad effects of IL-2 on immune responses. Proliferation, 
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differentiation, and other activation related events are triggered by IL-2IIL-2R interac-
tions in T and B lymphocytes, macrophages, NK cells, LAK precursors, eosinophils, 
and probably cells of the central nervous system (Ruscetti, 1990; Smith, 1980; 
Okamoto et aI., 1990). It is apparent from a number of studies that signal transduction 
pathways from the IL-2R are distinct from those that are coupled to the TCR (Albert 
et aI., 1985; Nau et aI., 1988). There is agreement from a number of systems that the 
extent of the proliferative response to IL-2 is dependent upon the interaction between 
IL-2 concentration, HA IL-2R density, and the duration of the IL-2IIL-2R interaction 
(Cantrell and Smith, 1984; Lowenthal et aI., 1985; Malek and Ashwell, 1985). 
Stimulation of the TCR activation pathway induces HA IL-2R expression, but once 
expressed, IL-2 itself enhances the expression of HA IL-2 binding sites. At high con­
centrations, IL-2 alone can also induce HA IL-2R sites via binding to intermediate 
affinity (� chain) receptors (Bich-Thuy et aI., 1987). 
Currently, it is known that the participation of at least two peptides is necessary 
for HA IL-2 binding to T cells (Robb et aI., 1984; Fujii et aI., 1986; Wang and Smith, 
1987; Fung et aI., 1988). Both human and murine IL-2Ra or p55 (Leonard et aI., 
1984; Nikaido et aI., 1984; Cosman et aI., 1984; Miller et aI., 1985) and IL-2R� or 
p70-75 (Kono et aI., 1990; Hatakeyama et aI., 1989b) have been cloned. The IL-2Ra 
chain alone can bind IL-2, but at an affinity far too low (Kd=10-20 nM) to be of 
significance physiologically; from a number of studies it appears unlikely that IL-2Ra 
plays an important role in IL-2 signal transduction (Kuziel and Greene, 1990). IL-
2Ra is expressed at very low levels in resting T cells and these surface levels increase 
dramatically when resting T cells are activated with Ag or mitogen (Cantrell and 
Smith, 1983; Wilkinson and MacLeod, 1988; Meuer et aI., 1984; Lowenthal et aI., 
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1985). IL-2 itself (Jankovic et aI., 1989; Plaetinck et aI., 1990; Smith and Cantrell, 
1985; Lowenthal et aI., 1989) plays an important role in amplifying the induction and 
maintenance of IL-2Ra and the mechanisms involved in regulating IL-2Ra gene 
expression have been studied extensively. Transcriptional regulation of this gene 
involves complex elements in the region 5' to the transcription start site (Smith and 
Greene, 1989; Plaetinck et aI., 1990). In addition, there are important DNA sequence 
motifs (Greene et aI., 1989; Pomerantz et aI., 1989) and DNA binding proteins that 
enhance (Lenardo and Baltimore, 1989; Freimuth et aI., 1989) or inhibit (Smith and 
Greene, 1989) the promoter of this gene. 
IL-2R�, in contrast to IL-2Ra, is constitutively expressed on the surface of 
resting T cells. However, recent reports have shown that the mRNA is constitutively 
produced in some lymphoid cells but not others (Kono et aI., 1990; Hatakeyama et aI., 
1989b). The genomic organization and promoter analysis of the human IL-2R� gene 
have recently been described (Shibuya et aI., 1990). In comparison to IL-2Ra, little is 
known of the Ag and IL-2 dependent regulation of IL-2R� transcription in either 
resting or activated cells. To define the role of IL-2R� for IL-2 binding, a number of 
transfection-reconstitution studies with T cell and fibroblast cell lines and work done 
with IL-2R�+ NK cells have shown that expression of IL-2R� is absolutely necessary 
for the production of intermediate affinity (IA) or HA IL-2 binding sites and for 
growth signal transduction (Hatakeyama et aI., 1989b; Okamoto et aI., 1990; 
Hatakeyama et aI., 1989a; Kono et aI., 1990; Tsudo et aI., 1989; Lotze et aI., 1987; 
Bich Thuy et aI., 1987; Aribia et aI., 1989; Minamoto et aI., 1990). 
Until recently, very little was known about IL-2R mediated signal transduction, 
and the pathways triggered by IL-2 binding to its receptor are still not entirely defined. 
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It is apparent that IL-2RP chain plays an important role in IL-2 signalling, as was 
suspected when the prominent 286 amino acid intracellular portion was identified 
(Hatakeyama et aI., 1989b). Although neither the IL-2Ra. or IL-2RP peptide have 
enzymatic domains (Hatakeyama et aI., 1989b; Saltzman et al., 1990), P chain is 
required for the phosphorylation of mUltiple protein substrates (M. 32 through 1 16) 
(Ferris et al., 1989). IL-2RP is itself phosphorylated on ser, thr, and tyr residues in 
lymphoid but not fibroblast IL-2R�+ cells (Sugamura et al., 1990), and its 
intracytoplasmic signal may be transmitted through an association with p561ck 
(Hatakeyama et aI., 199 1). Increases in [Ca2+]; are not required for IL-2-dependent cell 
growth. IL-2 binding to HA IL-2R is associated with phospho inositol breakdown and 
in some cells PKC translocation (Redondo et aI., 1988). Protein tyrosine kinases 
(PTK) of 97 and 57kD were purified from the IL-2R complex in an active form 
(Michiel et aI., 1990), and anti-PTK immunoprecipitates from IL-2 stimulated cells 
contained high levels of a phospholipid kinase that may be involved in IL-2R signal 
transduction (Augustine et aI., 1990). IL-2 dose-dependent tyrosine phosphorylation of 
various MW substrates (MW 100 to 57) has also been detected (Yamada et al., 1987; 
Ferris et aI., 1989; Ishii et aI., 1988). 
Thymic Differentiation 
T lymphocytes mature intrathymically from bone marrow or fetal liver 
precursors (Metcalf and Moore, 197 1). Among the earliest phenotypic markers 
expressed by prothymocytes are Thy 1 and Lyt l .  Thy 1 identifies lymphocytes as "T 
cells" for the duration of their existence in the body. The thymus contains many other 
cellular elements including epithelial cells, "nurse" cells, and bone marrow derived 
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accessory cells, that are crucial for proper T cell differentiation and development of 
self-tolerance. Additionally, there is increasing evidence that hormonal microenviron­
ments in the thymus influence T cell development (Nikolic-Zugic, 1991; Van Ewijk, 
1991 ). 
Thymocytes are divided into 4 major groups based on surface staining for CD4 
and CD8: CD4'8' (double negative, DN), CD4+8+ (double positive, DP), CD4+8' (sin­
gle positive, SP), and CD4'8+ (single positive, SP). Lineage relationships between 
these subsets have been defined, but the factors that influence the differentiation of DN 
thymocytes are largely unknown. It is known that prothymocytes that arrive from the 
bone marrow to populate the thymus are of DN phenotype. These cells can recon­
stitute all thymocyte populations and mature into either CD4 or CD8 SP peripheral T 
cells (MacDonald et ai., 1988). Moreover, it has also been reported that an immature, 
CD3'CD8+ SP cell can give rise to DP thymocytes in vitro (Nikolic-Zugic et ai., 1989), 
and this subset is capable of reconstituting DP and SP thymocyte subsets as well as 
peripheral T cell populations (Nikolic-Zugic and Bevan, 1988; Guidos et ai., 1989). It 
is thought that these cells arise directly from DN thymocytes (Guidos et ai., 1989; 
Mizushima et ai., 1989). To date, the factor(s) that promote the initial expression of 
CD8 on DN thymocytes has not been specifically identified. A recent series of reports 
has described a thymic stromal cell derived T cell growth factor (TSTGF) that 
stimulated the growth of thymic cells and synergized with phorbol esters and inter­
leukins to promote the growth of immature thymocytes (Mizushima et al., 1989; Sato 
et ai., 1988). The semipurified TSTGF from supernatants of a thymic stromal cell line 
promoted in vitro differentiation of a small percentage of DN thymocytes to a CD8 
single positive stage. Progression to the more mature DP and CD4 SP thymocytes did 
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not occur with the supernatant factor alone, but required the presence of the stromal 
cell monolayer (Fujiwara et aI., 1 990; Tatsumi et al., 1 990). Although a number of 
interleukins might be involved in thymocyte maturation (MacDonald et aI., 1 988 ;  
Shimonkevitz e t  aI., 1 987;  Jenkinson et al" 1 987;  Gotlieb e t  al., 1 990; Okazaki e t  aI., 
1 989), this group has recently ruled out IL-l through IL-7 as the critical differentiation 
factor present in TSTGF. Therefore, the exact nature of the factors which cause DN 
thymocytes to initiate production of surface CD4 or CD8 peptides is still unknown. 
Materials and Methods 
Mice. Virus-free DBAl2 and (C57BLl6 X DBAl2)F I (BDF,) mice were 
obtained from Harlan-Sprague-Dawley Laboratories, Indianapolis, IN. Mice were 
housed in a virus-free envirornnent, given food and water ad libitum, and screened 
regularly for pathogenic viruses using standard serological tests. 
Tumors. The P8 1 5  mastocytoma (H_2d) was obtained and passaged as 
described (Bear, 1 986). Briefly, P8 1 5  was passaged as ascites in syngeneic DBAl2 
mice and cryopreserved in RPMI- 1 640: 1 0% FCS: 1 0% dimethyl sulfoxide in liquid 
N2• Cells from ascites were used to inoculate TBH, to immunize mice, for in vitro 
experiments, and for passage. PHS-5 is a spontaneous mutant selected from P8 I 5  in 
8-azaguanine as described previously (Bear, 1 987), and is killed in the presence of 
hypoxanthine, aminopterin and thymidine (HAT). P8 1 5  and PHS-5 are antigenically 
indistinguishable, but PHS-5 was used for TBH to avoid outgrowth of metastatic tumor 
cells in vitro. PHS-5 cells were passaged as described for P8 1 5 . 
Inoculation of TBHs and Immunization. PHS-5 cells from ascites were washed 
in Hanks' balanced salt solution (HBSS) and injected i .d. on the abdomen at 1 06 
1 6  
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cells/mouse in 0.05ml for tumor bearing hosts (TBH). After 8-12 days of tumor 
growth, mice were designated "early TBH," while mice bearing 18 day tumors were 
designated "late TBH." For immunization, 2 X 106 P815 cells were mixed with 50 flg 
of formalin-killed Corynebacterium parvum (Burroughs Wellcome, Research Triangle, 
NC) and inoculated i.d. in a total volume of 0.05 ml. 
Mixed Lymphocyte Tumor Cell Cultures (ML Te). For establishment of 
ML TC, spleens were removed aseptically and pressed through 100-mesh screens in 
HBSS. Erythrocytes were lysed using Gey's hemolytic medium. Cells were then 
washed 3X in HBSS, and viable cells were counted by trypan blue exclusion and 
resuspended in complete medium (RPMI -1640 + 100 units/ml penicillin, 100flg/ml 
streptomycin, 2mM L-glutarnine, ImM sodium pyruvate, O.l mM non-essential amino 
acids, 10mM HEPES, 5x lOosM �-mercaptoethanol, 10% fetal bovine serum). Fifteen 
million spleen cells per well from P815 immune mice or PHS-5 TBH were cultured 
with 5xl0s mitomycin-C treated PHS-5 tumor cells in 24 well plates at 37°C in 5% 
CO2. All cultures included IX hypoxanthine-aminopterin-thymidine (HAT) (Sigma 
Chemical Co., St. Louis, MO) to prevent outgrowth of occult metastatic PHS-5 cells in 
the TBH splenocyte preparations. 
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Cytotoxicity Assays. After 6d in culture, ML TC cells were harvested, washed, 
resuspended in complete medium, and counted. Cytotoxic activity was assayed against 
5lCr-Iabelled target cells as described (Bear, 1986). Percentage of specific release 
(%SR) was calculated as: 
%SR = 100 X (cpm effector cells) - (cpm spontaneous release) 
(cpm maximum release) - (cpm spontaneous release) 
Spontaneous release was determined by culturing target cells in medium alone. 
Maximum release was determined by detergent lysis of labelled target cells. %SR 
values for triplicate samples were averaged, standard deviations obtained, and data 
were plotted as a function of effector:target ratio. 
Lytic units (LU) were calculated from cytotoxicity data, and a lytic unit was 
defined as the number of effector cells capable of causing lysis of 15% (LUI5) or 30% 
(LU30) of radiolabelled target cells. Cytotoxicity data reduction was performed using a 
nonlinear, least-squares fitting program (NOTLIN) (Pross et aI., 1981). Lytic units per 
culture represent the product of the L UII 06 cells and the total viable cells harvested 
per culture well. 
CTL Clones: GD 11.1 0 CTL were derived and maintained as described 
(Hoover et aI., 1991). Rested GD 11.1 0 CTL clones were obtained by washing CTL 
extensively prior to 3 days' culture in medium lacking lL-2. Rested CTL 
demonstrated <5% lysis of PHS-5 at effector:target (E:T) ratio=5: 1. Quiescent 
GDl1.10 cells were obtained 10 days after PHS-5 stimulation and 2 days after the last 
lL-2 feeding (IL-2 was not washed out). Quiescent CTL demonstrated >70% lysis of 
PHS-5 at E:T=5:1, but proliferated well only when both tumor cells and IL-2 were 
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added, not in IL-2 alone. 
Proliferation assay. To assess the DNA synthesis and cellular proliferation, 
Sx l04 cells were plated in each well of a 96-well flat-bottom tissue culture plate in 
complete medium. For stimulation of CTL clones, 2.Sxl04 mitomycin-C treated PHS­
S (PHS-Smc) tumor cells ± cytokines were added to each well. For assay of CTLL-2, 
Sx 1 04 cells were added to each well with various concentrations of cytokines. All 
wells were pulsed with 37kBq of 3H-thymidine 24h before harvest. At various 
timepoints, wells were harvested on a PHD cell harvester (Cambridge Teclmologies, 
Inc., Cambridge, MA). Liquid scintillation counting was performed on a Beckman LS 
SOOOTD instrument. Statistical significance was determined using a two-tailed 
Students' t-test for unpaired data. 
Cytokines. Unless otherwise specified, purified porcine platelet TGF�) (R&D 
Systems, Minneapolis, MN) was used and prepared per manufacturer's instructions. 
Accordingly, Illg TGF� was dissolved in a solution of 0.1 % bovine serum albumin in 
4mM HCl and stored for no longer than 2 months at 4°C. For use, this stock was 
diluted into complete medium and added to ML TC. Human recombinant TGF�) and 
murine recombinant TNFa were kindly provided by Genentech, San Francisco, CA. 
Human recombinant interleukin-2 was kindly provided by Hoffmann-LaRoche, Nutley, 
NJ. 
CTLL-2 culture. CTLL-2, an IL-2 dependent cytotoxic T cell line, was 
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originally derived from C57BLl6 mice immunized against allogeneic (DBAI2, H_2d) 
Friend leukemia cells (Baker et al., 1979). CTLL-2.TH, a non-cytolytic subclone 
obtained from Dr. Frank Fitch (University of Chicago, Chicago, IL), was used in these 
studies and will hence be referred to simply as CTLL-2. CTLL-2 were incubated in 
24-well plates (Costar, Cambridge, MA) at 5x l05/well and cultured at 37°C in a 
humidified atmosphere of 5% CO2:air in 2mllwell of complete medium (DMEM + 100 
units/ml penicillin, IOOllgiml streptomycin, 2mM L-glutamine, I mM sodium pyruvate, 
O.l mM non-essential amino acids, 5xlO-5M p-mercaptoethanol, 10% FCS) + 20U/ml 
recombinant human IL-2. Cultures were split every 2 days to prevent overgrowth, at 
which time fresh medium and IL-2 were added. For experiments, CTLL-2 were used 
2 days after the previous addition of IL-2, unless otherwise indicated. 
Assay of cell culture density by MTT. To assess cell culture density, 
lymphocytes were plated in each well of a 96-well flat bottom plate and cultured in 
0.2ml CM. For assay, O.l ml of medium was removed and 0.025ml of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; 5mgiml in saline; 
Sigma Chemical Co., St. Louis, MO) was added per well. Plates were incubated in 
the dark for 2h at 37°C prior to addition of 0.04N HCI in isopropanol (O. lrnl per well). 
Optical density values were obtained by absorption of light of wavelength 570nm. 
Assay of cell adhesion. To assess adherence of cells to the tissue culture plate, 
5xl 04 lymphocytes were added to each well of 96-well plates and cultured in O.2ml 
CM for 24h. For assay, another 0.25ml HBSS was added to completely fill wells, and 
plates were wrapped tightly with cellaphane. Plates were inverted, and centrifugation 
was done at 50 x g for 2min. Thus, cells were spun from the bottom to the top of 
each well. Following centrifugation, cellaphane was removed and nonadherent cells 
were decanted off with the medium. Wells were washed with O.lml HBSS and then 
0.1 ml CM was added to each well and MTT assay was performed to estimate the 
number of adherent cells remaining. 
Monoclonal antibodies CmAb), anti-sera, and immunofluorescence reagents: 
21 
Phycoerythrin (PE) conjugated mAb against murine CD8a (rat IgG2a, 53-6.7) and 
fluorescein isothiocyanate (FITC) conjugated mAb against murine CD8� (rat IgG} ,  53-
5.8), CD3£: (hampster IgG, 145-2Cl l), a�-TCR (hampster IgG, H57-597), y8-TCR 
(hampster IgG, GL3), ICAM-l (hampster IgG, 3E2) and LFA-l (rat IgG2b, 2D7) were 
obtained from Pharmingen, San Diego, CA. FITC conjugated mAb against murine IL-
2Ra (rat IgG2a, AMT-13), CD3£: (rat IgG2b, YCD3-1) and CD4 (rat IgG2b, YTS 
191.1.2) were obtained from GibcolBRL, Grand Island, NY. FITC conjugated rat 
mAb unreactive with murine splenocytes were obtained from Pharmingen and used as 
control reagents. These included rat IgG} ,  11014C; rat IgG2aK, R35-95; rat IgG2bK, 
R35-38. 
Mouse anti-rat K chains (mouse IgG2a, MAR 18.5), anti-CD8a (rat IgG2a, 53-
6.7), anti-CD8a (Lyt2.1 specific rat IgG2a, 116-13.1), anti-CD8a (Lyt2.2 specific rat 
IgG2b, 2.43), anti-CD4 (rat IgG2b, GK1.5), and anti-FcRy (rat IgG2b, 2.4G2) was 
obtained from the American Type Culture Collection (A TCC), and grown as ascites in 
pristane-primed nude mice. 
Purified anti-ICAM-l (rat IgG2a, MK- l )  was obtained from Dr. John Tew, 
Medical College of Virginia, Richmond, V A. Lyophilized rabbit-anti-rat Ig antiserum 
was obtained from CappelVOrganon Teknika, Malvern, PA and reconstituted with 
distilled water. 
Cell surface phenotyping by immunofluorescence with monclonal antibodies. 
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Cells were incubated with fluorochrome-conjugated mAb (1 Jlgl106 cells) in 50JlI 
phenotyping solution (1 % BSA, 0.1 % NaN) in PBS) on ice for 20-30 min. Cells were 
then washed twice in phenotyping solution. Fluorescence intensity of viable cells was 
analyzed on a Becton-Dickinson FACScan instrument equipped with a 15mW 488nm 
argon laser and appropriate excitation filters (Becton-Dickinson Immunocytochemistry 
Division, San Jose, CA). Background green channel fluorescence was determined after 
incubating cells with isotype-matched, irrelevant FITC-conjugated mAb obtained from 
Pharrningen. Background orange channel fluorescence was determined after incubating 
cells with an excess of unconjugated anti-CD8 (53-6.72) prior to staining with PE­
conjugated anti-CD8. Dead cells were excluded from analysis based on propidium 
iodide staining and forward angle light scatter. Data were collected on 5,000 or 
10,000 cells with log amplification and analyzed on a Hewlett Packard series 300 
computer (Portland, OR). 
Staining of cells with IL-2 ligand. Biotinylated IL-2 was obtained from R&D 
Systems, Minneapolis, MN . Cells were incubated with biotinylated IL-2 on ice for 30 
min prior to being washed twice in phenotyping solution. Next, cells were incubated 
with 5JlI PE-conjugated streptavidin (Tago Immunologicals, Burlingame, CA) for 30 
min on ice, and washed twice. Fluorescence intensity of viable cells was analyzed on 
a Becton-Dickinson FACScan instrument equipped with a 15mW 488nm argon laser 
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and appropriate excitation filters (Becton-Dickinson Immunocytochemistry Division, 
San Jose, CA). Background orange channel fluorescence was determined after 
incubating cells with PE-conjugated streptavidin alone. Dead cells were excluded from 
analysis based on propidium iodide staining and fluorescence in channel 3. Data were 
collected on 5,000 or 10,000 cells with log amplification and analyzed on a Hewlett 
Packard series 300 computer (Portland, OR). 
cDNA probes and Northern analysis. cDNA probes used in these studies were 
kindly provided by the following investigators: IL-2Ra from Dr. R. Germain (Miller 
et aI., 1985), IL-2RP from Dr. T. Tanaguchi (Okamoto et aI., 1990), Granzyme B 
from Dr. R.C. Bleackley (Lobe et aI., 1986), CD8a (Zamoyska et aI., 1985) and CD8P 
(Gorman et aI., 1988) from Dr. Jane Parnes, and p-actin from Dr. L. Kedes (Gunning 
et aI., 1983). DNA was nick translated with a32p_ labelled deoxynucleotide 
triphosphates (lCN Biomedicals Corp., Costa Mesa, CA). Total RNA was prepared 
using RNAzol B (Biotecx Laboratories, Houston, TX). Accordingly, 5x107 
lymphocytes were harvested and washed xl  in HBSS in 50cc polypropylene tubes. 
Cell pellets were disrupted by vortexing (high speed, 5sec) and RNA extracted by 
addition of 0.2ml of RNAzol B (a guanidine isothiocyanate + phenol preparation) per 
106 cells. This lysate was transferred to 1.5ml snap-cap tubes and to this O. l ml ice­
cold chloroform (per 1ml lysate) was added. Samples were vortexed (high speed) for 
15sec and then incubated on ice for 5-15min. Samples were next centrifuged at 
14,000g (Eppendorf Micro Centrifuge 541 5, Brinkman Instruments Co., Westbury, 
N. Y.) at 4°C for 15min. After centrifugation, the homogenate consisted of two phases: 
a lower blue organic phase (phenol/chloroform) and an upper clear aqueous phase. 
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The organic phase and interface contained DNA and protein, whereas the RNA 
remained soluble in the aqueous phase. The aqueous phase was pi petted off, and 
transferred to a clean microfuge tube, an equal volume of ice-cold isopropyl alcohol 
was added and this solution was vortexed for 15sec. Samples were incubated on ice 
for 15-60min and then spun (14,000g, 4°C) for 15min. The RNA pellet was identified 
as a white/opaque streak on the side of the tube near the bottom. Supernatant fluid 
was decanted or aspirated off and the pellet was washed once with cold 75% ethanol. 
Ethanol was aspirated and RNA was dried under vacuum for 10-15min. Dried RNA 
was re-dissolved in 0.050-0.2ml of diethylpyrocarbonate (DEPC)-treated, RNAase-free 
dH20. Incubation ( lOmin) at 60°C was sometimes required to completely re-dissolve 
the RNA. A 10- or 20-fold dilution of the sample was made into water and the RNA 
concentration measured by spectrophotometry and routinely had a 260/280 ratio of 1.8-
2.0. [RNA] in j.lg/J..t1 = OD260 x 0.04 x dilution. The RNA was prepared for 
electrophoresis by adding the following to a microfuge tube: 10j.lg RNA, 25j.ll 
formamide, 2.5j.l1 of 20X 3-N-morpholino propane sulfonic acid (MOPS; O.4M MOPS 
prepared as 100mM Na Acetate + 20mM EDT A, pH to 7.0 with NaOH or acetic acid), 
8.9j.ll formaldehyde, QS to 50j.ll with dHP, 5j.ll bromphenol blue (BPB; 0.25% stock: 
0.25g in 100ml IX MOPS), 5j.ll 0.5mglml ethidium bromide (optional). This mixture 
was heated to 60°C for 5min and then quick-chilled. 
The gel was prepared as follows: One gram electrophoresis grade agarose + 
5ml of 20X MOPS + 77ml milli-Q dHP + stir bar in 500ml Erlenmeyer flask. This 
mixture was brought to a boil while stirring on a stirlheat plate ( lOmin) then allowed 
to cool to 60°C. Just prior to pouring, 18ml of formaldehyde (37%, Fisher) was 
added. The agarose solution was added to the level gel plate under the exhaust hood. 
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The agarose was allowed to to polymerize, incubated at 4°C ( IS-30min) then placed in 
the gel rig. IX  MOPS (made up in bulk as 200ml 20X MOPS in 4L of milli-Q dH20) 
was added until the gel was covered by O.S- Icm buffer. The RNA sample was added 
and electrophoresed for 4-18h at IS to SOV. Electrophoresis was complete when the 
BPB dye had migrate 3/4 of the length of the gel. The gel was photographed (with a 
ruler along one edge) on a UV light box with black & white polaroid film (f-stop = 
S.6, shutter speed 1/8 sec). The gel was next washed with 20X SSC, with agitation at 
2SC for 20min and then RNA was transferred overnight to a nitrocellulose membrane. 
Equal RNA loading of lanes was confirmed by ethidium bromide staining of gels 
before and after transfer. RNA was immobilized to the nitrocellulose by baking at 
80°C under vacuum. Specific mRNA were detected by hybridization with 
radiolabelled cDNA, prepared using the Bethesda Research Labs (BRL) Nick 
Translation Kit. Briefly, SJ.ll of solution A2 (cold dATP, dGTP, and dTTP) + SJ.ll of 
solution C (DNA pol I + DNAse I), 7J.lI [a32P]dCTP (specific activity 10mCi/ml), and 
O.SJ.lg cDNA was brought to SOJ.ll total volume with soln E (dH20) and allowed to 
incubate I h at IS°C. After nick translation, radioactive DNA was separated from 
unincorporated e2p]dCTP using Elutip-D columns (Schleicher & Schuell). Double 
stranded nucleic acids (DNA or RNA) binds to the cellulose acetate in the column 
during low salt conditions (0.2M NaCl) and is eluted in high salt buffer (1 M NaCl), as 
binding affinity between the DNA and cellulose is lower at higher ionic strenghts. 
Blots were hybridized with 106 cprn/ml of a32P-labelled cDNA in hybridization 
medium (SO% formamide, lOX SSC, SX Denhardt's  solution, 100J.lg/ml denatured 
salmon sperm DNA, and IS% dextran sulfate). After washing under high stringency 
conditions, radioactivity was detected by autoradiography on Kodak XO-MA T AR film 
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(Eastman Kodak Co., Rochester, NY) with intensifying screens at -80°C. Before re­
probing, blots were placed in O. lX  SSC, 0.1% SDS at 90-100°C for 3-5min, and 
autoradiography performed to ensure complete removal of the previous probe. Hybrid­
ization was quantitated by densitometric scanning of appropriately exposed 
autoradiograms (Shimadzu CS-9000, Shimadzu Scientific Instruments, Columbia, MD). 
Inhibition of DNA and RNA synthesis. To arrest cell growth, DNA synthesis 
was inhibited by incubation of CTLL-2 in hydroxyurea (Young et ai., 1967) (HU; 
Sigma, St. Louis, MO). To determine the optimal conditions for inhibition of CTLL-2 
cell growth, an HU dose-response curve was constructed by incubating cells with 
various doses of HU prior to 3H_ TdR addition. In this system, 1mM HU reliably and 
completely inhibited growth of CTLL-2. Loss of cell viability was only evident after 
48h. To further confirm the efficacy of this treatment, DNA content of propidium 
iodide-stained nuclei was analyzed on an EPICS 753 cell sorter (Coulter Electronics, 
Hialeah, FL). Eighteen h after HU treatment, >95% of cells had accumulated in 
Got'GI. RNA synthesis was inhibited by 8h treatment of cells with 5llg/ml 
Actinomycin-D (Sigma) dissolved in ethanol (final [EtOH]= 0.5%). Cell viability after 
Actinomycin-D treatment was 2: 71 %. 
CTLL-2 subset enrichment (panning). CTLL-2 cells were treated with 20U/ml 
IL-2 + 1ng/ml TGFp on days 0 and 2. On day 3, cells were harvested, incubated with 
a 1/50 dilution of anti-CD8 (53-6.72) ascites, washed, and incubated at 4°C on a rabbit 
anti-rat Ig (Capell/Organon Technika, Malvern, PA; 4°C, 45min) coated bacteriologic 
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grade petri dish (Baxter Healthcare Corp., McGaw Park, 1L). Non-adherent cells were 
harvested by gently swirling and treated with rabbit C obtained from Accurate Chemi­
cal and Scientific Corp., Westbury, NY (CDS-depleted). Adherent cells were 
harvested by vigorous pipetting (CDS-enriched). To determine the effectiveness of 
separation, CDS-depleted and CDS-enriched populations were incubated with anti­
CDSu mAb, washed, stained with FITC-conjugated goat anti-rat 19 and analyzed by 
flow cytometry. 
Activation and culture of thymocytes. Mice were sacrificed by CO2 inhalation 
and after thymectomy, a thymocyte suspension (106 /m!) was prepared in complete 
medium with 50 nM PDBu (Sigma, St. Louis, MO), 1 11M 10 (Calbiochem, San Diego, 
CA) ± 20U/ml r1L-2 ± 1ng/ml porcine platelet TGFp in 50ml polypropylene tubes 
(Costar, Cambridge, MA). After incubation at 37"C in humidified air with 5% CO2 
for ISh (on day 1), cells were washed 3X in warm HBSS to remove PDBu (McCrady 
et aI., 19S5) and re-cultured in complete medium ± 20U/ml r1L-2 ± 1ng/ml TGFp at a 
cell density of 2.5x1 05 cells/well in 4S-well plates (Costar). One ng/ml TGFp was 
chosen because it was optimal for the induction of CDS in CTLL-2 cells. Cultures 
were split as necessary to prevent overgrowth; fresh medium, 1L-2, and TGFp were 
added every 2-3 days. 
Preparation of DN and CDS SP thymocytes. Single cell suspensions of 
thymocytes were incubated in cytoxicity medium (Accurate Chemical and Scientific 
Corp.) with a 1/50 dilution of anti-CD4 (GK1.5) ascites, washed, incubated with 1150 
dilution of mouse anti-rat 19K chain (MAR1S.5) ascites, washed, and treated with 
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rabbit C (1112 dilution, Accurate Chemical and Scientific Corp.). Next, thymocytes 
were incubated with 1/50 dilution of anti-CD8a (116-13.1), washed, and incubated on 
a rabbit anti-rat Ig (which is cross reactive with mouse Ig) coated plastic petri plate at 
4°C for 45min. Non-adherent cells were removed by gentle swirling of the plate; 
adherent cells were removed only after vigorous washing. Adherent cells were >96% 
CD8 SP and were used without further treatment. Non-adherent cells were further 
treated with a 1150 dilution of GK1.5 and 116-13.1, followed by a second treatment 
with rabbit C. Typically, 0.5 to 3% of input cells remained, and were approximately 
95% CD4'CD8- as determined by immunofluorescence using anti-CD8a (53-6.72) and 
anti-CD4 (YTS 1 91 .1 .2). These conjugated antibodies do not cross-react with sites 
recognized by the cytotoxic antibodies used for C depletions (data not shown). 
Separation of CD8+ cells from DN thymocyte cultures treated with TGFB. DN 
thymocytes were harvested after 6 days in culture with IL-2 + TGFp, incubated with 
1150 dilution of anti-CD8 (53-6.72) ascites, washed and incubated on a rabbit anti-rat 
Ig coated petri dish (4°C, 45min). Nonadherent (CD8-) cells were removed by gentle 
swirling of the plate; adherent (CD8+) cells were removed only after vigorous washing 
with cytotoxicity medium. 
Chapter 1 
Inhibition of Tumor-Specific Cytotoxic T Lymphocyte 
Responses by Transforming Growth Factor-PI 
Author' s  note: The first chapter of this dissertation is derived in part from a 
published manuscript authored by myself, Dr. Shelley Hoover, Dr. Brian Susskind, Ms. 
Sandra Barrett, and Dr. Harry Bear (lnge et aI., 1992b). Many of the figures in this 
chapter contain data derived from experiments that were designed by myself with 
assistance from my graduate advisor, and performed with the technical assistance of 
Laboratory Specialist Sandra Barrett (Tables 1.01-1.04 and Figures 1.01-1.02). 
Tumor-specific CTL clones used in this work were laboriously generated by Dr. 
Shelley Hoover during her post-doctoral fellowship in the lab (Hoover et aI., 1991). 
Further, Dr. Hoover' s  contribution of the data shown in Figure 1.06 is gratefully 




TGFp has been shown to inhibit the activation of lymphokine activated killer 
(LAK) cells by IL-2 (Kuppner et aI., 1988; Mule et aI., 1988; Jin et aI., 1989), as well 
as the generation of allospecific cytotoxic T lymphocytes (CTL) in primary mixed 
lymphocyte reactions (Ranges et aI., 1987; Wallick et aI., 1990; Fontana et aI., 1989; 
Shalaby and Amman, 1988). Inhibition of T cell responses and LAK activation by 
TGFp, along with its secretion by malignant cells (Tada et aI., 1991; Arrick et aI., 
1990; Hirte and Clark, 1991), has led to the proposal that this cytokine may play a key 
role in the in vivo immunosuppression associated with tumor progression, and may 
severely limit successful immunotherapy of cancer. It has been shown, for example, 
that transfection of a regressor tumor line with the gene for TGFp caused it to grow 
progressively in vivo (Torre-Ami one et aI., 1990). There are convincing data showing 
that malignant cells produce TGFp and that TGFp inhibits primary immune responses, 
but studies showing that TGFp directly inhibits the responses of host T lymphocytes to 
syngeneic tumor cells are lacking. The data presented in this chapter demonstrate that 
TGFp inhibits in vitro generation of antitumor CTL. This observation may in part be 
attributed to an indirect effect on IL-2 production and/or by a direct effect on 
proliferation of memory CTL. 
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Results 
TGF{3 Suppresses en Generation from P8i5 Immune Mice 
Splenocytes from mice immunized with P815 + C. parvum contain helper T 
lymphocytes (Th) and memory CTL that can be re-activated in vitro when stimulated 
with autologous tumor cells during ML TC (Bear et aI., 1988). Since TGFp has been 
implicated in suppression of anti-tumor immunity, we sought to determine whether 
exogenously added TGFp would inhibit anti-tumor CTL generation. When purified 
TGFp was added to ML TCs of P815 immune splenocytes from DBN2 or BDF 1 mice, 
marked suppression of the CTL response was seen (Figure 1.01 and Table 1.01). With 
doses ranging from 0.675 to 10ng/ml TGFp, we consistently observed >80% inhibition 
of lytic activity (Table 1.02). Similar results were obtained with recombinant human 
TGFp (data not shown). 
In addition to the effect on cytolytic activity, the addition of TGFp to ML TC 
typically resulted in a moderate (30%) reduction in the number of viable cells per well 
at the end of the culture period, especially at higher doses of TGFp. Similar to 
previous reports for primary allogeneic MLRs (Ranges et aI., 1987), we only observed 
inhibition of CTL activity when TGFp was added at the initiation of the cultures. 




Effect of IL-2 on TGF(3 Treated MLTC 
Next, we sought to determine whether TGFp might be acting to limit the 
availability of IL-2, as suggested by others (Tada et aI., 1991). In two separate ex­
periments, when 5 or 20 U/ml rIL-2 was added with 2 nglml TGFp, inhibition was 
reversed by 50-80% (Table 1.03). However, cytolytic activity was not restored 
completely to control levels by 5 U/ml IL-2, and groups treated with IL-2 + TGFp 
were less cytotoxic than groups treated with IL-2 alone, especially at low E:T ratios. 
To rule out the possibility that rIL-2 was inducing LAK activity in our system, rather 
than rescuing the CTL response, we also treated normal DBAl2 splenocytes with 5, 20, 
or 1,000 U/ml rIL-2. Only at 1,000 U/ml was significant LAK activity against P815 
detected. In this same experiment (and others (McKinnon et aI., 1990)), effector cells 
from ML TC supplemented with 5 or 20 U/ml IL-2 did not lyse the LAK sensitive B 16 
melanoma, indicating that low dose IL-2 was insufficient to generate LAK cells from 
DBAl2 early TBH splenocytes. Finally, in our hands, P815 cells are generally quite 
resistant to lysis by DBAl2 LAK cells. 
Effect of TGF(3 on Tumor-Specific cn Clones 
The above data suggest that TGFp inhibits the in vitro activation of anti-tumor 
effector CTL, at least in part, by reduction of cytokine availability. However, since 
addition of low doses of exogenous IL-2 to TGFp-treated ML TC did not result in 
complete restoration of cytotoxic activity to control levels, TGFp might also act 
directly on the proliferation or maturation of memory CTL populations. We derived 
33 
several highly lytic, homogeneous CTL lines and clones from the spleens and axillary 
draining lymph nodes of PHS-5 TBH (Hoover et ai., 1991) and the salient 
characteristics of these cells deserves brief mention. CTL clone GD I I  was derived 
from the spleen of a PHS-5 TBH and is Thy 1.2+, CD8+, CD4·, IL-Ra+ and 
specifically cytolytic for P815 mastocytoma cells (Hoover et ai., 1991). Subclones of 
GDll were maintained by weekly stimulation with PHS-5 tumor cells and were fed 
20U/ml rIL-2 every 3 days; as long as IL-2 was provided, CTL activity remained high 
(80-90% lysis at E:T=5: 1). Five to seven days after tumor stimulation, while being 
fed rIL-2 every 3d, GDl l CTL lose proliferative responsiveness to rIL-2 (Figure 
1.03), but remain >90% IL-2Ra positive (Figure 1.04) and highly cytolytic (>70% 
lysis at E :T=5: I); thus, such cells are termed "quiescent-lytic. " These cells require 
tumor cells (antigen source) and exogenous IL-2 to trigger maximal proliferative 
responses to IL-2. In contrast, if rIL-2 is washed out of GDI I  cultures and these CTL 
are maintained in complete medium alone for two to four days, the cells lose the 
ability to proliferate in response to IL-2 (Figure 1.05), become <5% IL-2Ra+ (data not 
shown), and are essentially non-cytolytic (Figure 1.06)--a stage termed "rested." 
We sought to determine what effect TGFp had on the proliferation of rested, 
GDI I  CTL clones in response to rIL-2 and tumor cell antigen. When rested GDIl.lO 
subclones were stimulated with tumor cells and IL-2, treatment with 5 or 10 ng/ml 
TGFp markedly inhibited short-term proliferation (Figure 1.07). In contrast to the 
effect on cell proliferation, the IL-2-dependent reactivation of cytotoxic activity was 
not diminished by TGFp treatment (Figure 1.08). Interestingly, when TGFp (5 or 
10ngiml) was added to quiescent-lytic GDl1.1 0, neither proliferation (Figure 1.07) nor 
cytotoxicity (data not shown) was inhibited. 
Discussion 
TGFr is a multifunctional cytokine made by numerous normal tissues, 
including T lymphocytes, and also by many tumors. Most tissues, including cells of 
the immune system, have receptors for TGFr. Many studies to date have reported the 
negative modulatory effects of TGFr during primary T lymphocytes responses to 
antigen or mitogen (Ranges et aI., 1987; Mule et aI., 1988; Morris et aI., 1989; Kehrl 
et aI ., 1986b). We have examined the effects of TGFr on secondary in vitro anti­
tumor CTL responses. P81S-immune splenocytes contain memory CTL that, when 
cultured with mitomycin-C treated P8 I S, proliferate and differentiate into tumor­
specific effector CTL that can be detected by cytotoxicity assay (Bear et aI . , 1988). 
The generation of class I-restricted CTL in ML TC depends on the presence of tumor 
cells bearing MHC class I, syngeneic accessory cells, and MHC class II-restricted 
CD4+ helper T cells (Bear et aI . , 1988). When TGFr was added in nanogram quanti­
ties at the initiation of ML TC from tumor immune mice, we consistently saw >80% 
inhibition of CTL activity. If addition of TGFr was delayed for 24h or more, the 
CTL response was not inhibited, favoring the hypothesis that T memory cells, like 




I t  has been suggested that the generalized suppression of lymphocyte responses 
in tumor bearing hosts and the mediation of this immunosuppression by TGF� is 
primarily the result of inhibiting CD4+ T helper cell activation and IL-2 production 
(Tada et a! . ,  1 99 1 ;  Tada et a! . ,  1 990; Kuppner et a! . ,  1 988) .  To determine what role 
limiting IL-2 availability in ML TC may play in the effect of TGF�, we added recom­
binant IL-2 to TGF�-treated ML TC; 5 U/ml IL-2 largely but still incompletely 
restored CTL activity; 20U/ml restored activity to near control levels. Parallel cultures 
of normal splenocytes treated with the same doses of IL-2 were incapable of lysing 
P8 1 5  or allogeneic LAK sensitive targets, thus ruling out LAK induction as an 
explanation for the increased killing in IL-2 supplemented ML TC (furthermore, LAK 
are TGF� sensitive). In sum, these data indicate that one point at which TGF� blocks 
the secondary CTL response of P8 1 5-immune splenocytes to tumor cells is at the level 
of Iymphokine production by Th cells. This is in agreement with recent studies (Tada 
et a! . ,  1 99 1 )  showing that tumor cell supernatants containing TGF� inhibited the CTL 
response to haptenated self which, like the response to P8 1 5  (Bear et a! . ,  1 98 8), re­
quires CD4+ Th cells. The CTL response to alloantigen, in contrast, can proceed 
without CD4+ cells, using IL-2 from CD8+ Th cells (Mizuochi et a! . ,  1 985) and was 
relatively resistant to inhibition by TGF� (Tada et a!., 1 99 1 ) . 
However, since the inhibition of ML TC was not completely reversed by 
addition of low dose IL-2, it was still possible that TGF� inhibited CTL by additional 
mechanisms other than inhibition of cytokine production. To measure direct effects of 
TGF� on memory CTL, we employed cloned, homogeneous populations of P8 1 5-
specific CTL. Rested CTL clones are analogous to pre-effector CTL as both are non­
cytolytic, and display low levels of IL-2Ra until re-activated by tumor stimulator cells 
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and IL-2, at which time they proliferate and become specifically cytolytic for tumor 
cells. The proliferation of rested CTL clones was inhibited by 80-90% in the presence 
of 2.5 to 1 Onglml TGF�. In contrast to rested cells, the proliferation of quiescent-lytic 
CTL was not inhibited by TGF�. TGF� blocks the exit of T cells from G, (Stoeck et 
aI., 1989a; Morris et aI., 1989), and therefore it is possible that the rested population is 
more sensitive to TGF� because more cells in this group exist in the GclG, phase of 
the cell cycle than quiescent-lytic cells. These data are also congruent with our find­
ings that CTL activity was inhibited only when TGF� was added at the start of ML TC 
but not 24, 48 or 96h after initiation of the in vitro secondary response. 
IL-2 is necessary for both the up-regulation of cytotoxicity and the proliferation 
of rested CTL clones. The fact that TGF� inhibited tumor + IL-2 dependent growth 
of CTL but not the up-regulation of cytotoxicity indicates that TGF� can discriminate 
between two distinct signalling pathways that are triggered by IL-2 binding to these 
CTL. This inability of TGF� to inhibit activation of killing activity is in agreement 
with Shalaby et al. who found that TGF� inhibited the generation of allospecific CTL 
but did not affect cytolytic function of such CTL generated in the absence of TGF� 
(Shalaby and Amman, 1988). The fact that IL-2-dependent development of 
cytotoxicity was resistant to TGF� suggests that TGF� may discriminate between two 
distinct pathways triggered by IL-2R ligation. Such a hypothesis would predict that all 
responses to IL-2 may not be targets for the inhibitory action of TGF�. Current 
themes in the cytokine receptor literature portray single surface receptor types com­
municating with multiple second messenger pathways, with much molecular "crosstalk" 
occurring intracytoplasmically. Thus, it is not difficult to imagine that surface 
receptors that have multiple functions (such as growth and differentiation in the case of 
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IL-2R) may feed into multiple divergent signalling pathways which might be regulated 
differently by cytokines such as TGFp. 
In summary, these studies demonstrated that the immunosuppressive activities 
of TGFp observed by others in primary T cell responses can be extended to secondary 
in vitro CTL responses directed against syngeneic tumor cells. In experiments 
designed to identify the mechanism(s) of inhibition, our data suggest that TGFp acts at 
multiple steps leading to the activation of anti-tumor CTL, including inhibition of IL-2 
production, as has been shown for primary responses (Ranges et aI., 1987; Tada et aI., 
1991; Espevik et aI. ,  1987). Additionally, a direct anti-proliferative effect on resting 
CTL clones stimulated with IL-2 and tumor cells was observed. Investigation of the 
effects of TGFp on mitotic responses of T cells would add to our understanding of 
TGFp-mediated immunosuppression. 
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Table 1 .0 1 :  Suppression of MLTC by TGF�. Splenocytes from P815-immune 
DBA/2 (Experiments 1 and 2) or BDFI (Experiments 3-5) mice were used to 
establish MLTC. TGF� was added to cultures on day 0 and after 6 days 
chromium release assay was performed. Cytotoxic activity was compared between 
groups and LUso per 106 cells and per culture were calculated. LU/Cx = Lytic 
units per culture, calculated as the product of LU / 106 cells and viable cell counts 
per well in each group. 
Treatm�nt; PHS-5mc IQELi % L�Sis 
40: 1 
Expt 1 20 
+ 59 
+ 10ng/ml 24 
Expt 2 5 
+ 3 1  
+ 5ng/ml 15 
Expt 3 8 
+ 78 
+ 5ng/ml 35 
Expt 4 3 
+ 56 
+ 5ng/ml 12 
Expt 5 4 
+ 6 1  

















llio/106+SD LU ICx 
1 .8±0.4 5 
1 1.3±0. 1 33 
2.0±0.2 6 
0. 1±0. 1  0 
32.6±4.5 78 
2.4±0.3 5 
0.6±0. 1 2 
23.4±4.3 56 
3.6±0.5 7 
0.2±0. 1  1 
15.3±2.9 4 1  
1 .0±0.2 3 
0.2±0.0 1 
7 1 .0± 2 1  284 
5.3±0.3 15 
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Table 1.02: TGFp dose response for inhibition of ML TC. ML TC cultures were 
established with P815 immune DBN2 splenocytes. The first row shows results 
without tumor stimulator cells. O-lOnglml TGFp was added to MLTC on day O. 
Percent lysis is shown at E:T=40:1. LUI5 or LU30 per 106 cells were calculated from 
% lysis data and are shown ± SD. LU/Cx = Lytic units per culture, calculated as the 
product of LUll 06 cells and viable cell counts per well in each group. 
TGFB %Lysis LUI51l 06 LU/Cx 
PHS-5mc (40: 1) 
0 -1 <0 <0 
+ 0 25 5.1±0.5 16 
+ 0.68 4 0.7±0.1 2 
+ 1.25 2 0.4±0.2 3 
+ 2.5 8 1.2±0.1 3 
+ 5 6 0.9±0.1 1 
+ 10 6 0.9±0.1 2 
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Table 1.03 : IL-2 reversal of TGF�-mediated suppression of ML TC. Splenocytes from 
P815-immune DBAl2 mice were used to establish ML TC. 107 splenocytes were either 
unstimulated or stimulated with 5xl05 PHS-5mc ± 2ng/ml TGF� ± 5 or 20V/ml 
recombinant human IL-2. Nonnal spleen cells were cultured with various doses of IL-
2. On day 6, cultures were assayed for cytotoxic activity against 51Cr labelled P815 
cells, and these data are shown as % specific lysis. Lytic units per 106 cells and LV 
per culture well (LV/Cx) are also shown for each group. A parallel assay against 51Cr 
labelled B16 cells yielded no significant lysis « 3% lysis at E:T=40:1 or 20:1) by these 
same experimental groups. However, the nonnal splenocytes cultured in 1,000 V/rnl 
IL-2 (last row) did lyse these LAK sensitive targets (25% and 18% lysis at E:T=40: 1 
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Figure 1 .0 1 :  TGFp inhibits CTL generation from P8 l S-immune splenocytes. MLTC 
established with splenocytes from P8lS-immune mice were either "unstimulted" = 
cultured in media alone; "stimulated" = cultured with mitomycin-C treated PHS-S 
cells; "stimulated + Sng/ml TGFpt' = PHS-Smc + Sng/ml TGFp added at initiation of 
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Figure 1.02: Effect of TGFp added to ML TC on various days. ML TC were 
established with BDF, immune spleen cells. Five ng/ml TGFp was added on days 0, 
1, 2, or 4. Percent lysis at E:T=40: 1 is shown ± SD; similar results were obtained at 
other E:T ratios and LU301106 cells are shown above each bar. 
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Figure 1.03: CTL clones lose proliferative responsiveness to IL-2 (ie., become 
quiescent) late after antigen exposure. GD 11.17 clones were harvested from culture, 
washed, and stimulated in 24-well plates with PHS-5mc + 20U/ml IL-2. On days 3, 4, 
6, 7, 8, and 9 after stimulation, cells were harvested from 24-well plates, washed, 
plated in 96-well plates with various concentrations of IL-2 + 37kBq of tritiated 
thymidine. Isotope incorporation was measured over a 24h period and plotted as a 
function of time after initial tumor stimulation. Points represent arithmetic mean cpm 
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Figure 1.04: Quiescent CTL clones are IL-2Ra+. GDI1.17 cells were harvested from 
culture (5 days after previous stimulation with tumor cells) and treated with 20U/ml 
IL-2 with (A) or without (B) fresh tumor stimulator cells. Three days later, cells were 
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Figure 1 .05 : Rested CTL clones do not proliferate in response to IL-2. GD I 1 . l 7  cells 
were harvested from culture 5 days after previous stimulation with tumor cells and 
washed free of IL-2. These cells were "rested" by culture in the absence of IL-2 for 
an additional 4 days prior to stimulation with 0, 1 0, or 20U/ml IL-2 (BARS on right) . 
The response of these rested cells was compared to that of cells that were activated by 
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Figure 1 .06: Rested CTL clones are non-cytolytic. Cytotoxic activity (against 5 1Cr 
labelled P8 1 5) of rested GD 1 1 . 1 7  CTL clones (9 days after tumor stimulation, 4 days 
after washout of IL-2) was compared to cytotoxic activity of active CTL clones (2 
days after tumor stimulation, 2 days after previous feeding of IL-2). 
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Figure 1 .07:  TGF� inhibits proliferation of rested CTL clones. Fifty thousand rested 
or quiescent CTL clones were cultured ± 20U/ml IL-2 ± TGF� ± 2.Sx l 04 PHS-Smc 
per well in 96 well flat-bottom plates. On day 2, 37kBq 3H-thymidine was added per 
well and cells were harvested on day 3 .  The proliferation of rested GDl 1 . 1 0  + PHS-S 
+ IL-2 + 2.Sng/ml TGF� was significantly different from the positive control group 
that did not receive TGF�, p<O.OS by Students' t-test. 
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Figure 1 .08 :  TGF� does not inhibit cytolytic activation of rested CTL clones. 5 x l 05 
rested GD 1 1 . 1  0 CTL were added to each well of a 24 well plate with 2 .5x 1 05 PHS-
5mc and 20U/ml IL-2 ± 5ng/ml TGF�. On day 2, cultures were assayed for cytolytic 
activity against 5 1 Cr labelled PHS-5 tumor cells. Baseline cytotoxic activity on day 0 
is also shown ± SD (bar, E:T ratio = 5 : 1 ). LU30 ± SD values for control and TGF�­
treated cultures were 274±36 and 230±28, respectively. 
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Chapter 2 
Effect of TGF� on T Lymphocyte Growth 
Introduction 
The data presented in Chapter 1 above demonstrated that TGF� inhibited the 
generation of CTL in ML TC culture and suggested that this effect was at least in part 
a result of decreased IL-2 production. However, the proliferation of cloned CTL was 
also inhibited by TGF� in the presence of exogenous IL-2. Thus this inhibition 
appeared to be secondary to a direct antiproliferative effect on these cells. We chose 
next to investigate whether the anti proliferative effect of TGF� on T lymphocytes 
might stem from inhibition of IL-2 responsiveness. 
TGF� regulates growth of numerous cancerous and non-neoplastic cell types and 
the inhibition of growth factor-dependent proliferation in epithelial and mesenchymal 
cells appears to be downstream of the interaction of growth factors with their receptors 
(Laiho et aI . ,  1 990a). In hematopoietic and lymphoid systems however, TGF� has 
been shown to modulate cytokine receptor levels, suggesting the possible existence of 
more complex levels of cell cycle regulation in leukocytes (Jacobsen et aI . ,  1 99 1 ;  
Kehrl et aI . ,  1 986b; Kuppner et aI . ,  1 988) .  It was also suggested that TGF� alters bio-
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chemical events induced by intennediate affinity IL-2R ligation in NK cells (Ortaldo et 
a! . ,  1 99 1 ) . With respect to T cells however, there are scant data concerning the effect 
of TGF� on high affinity IL-2R-induced events, and the physiology of these two 
receptor types (intennediate and high affinity) may differ. There are, in fact, con­
flicting reports regarding the effect of TGF� on IL-2Ra chain expression with some 
reports showing increases, some showing decreases, and others showing no change 
(Smyth et a! . ,  1 99 1 ;  Kehrl et a! . ,  1 986b; Stoeck et a! . ,  1 989a; Ruegemer et al . ,  1 990; 
Wahl et a! . ,  1 988) .  
The tumor-specific CTL clones described in Chapter 1 above grow relatively 
slowly, require much manipulation, and require the addition of live tumor cells for 
maintenance, which limits their usefulness for initial studies. CTLL-2 is an IL-2 
dependent, non-neoplastic T cell line that was originally derived as a cytotoxic T lym­
phocyte clone against Friend leukemia cells. These Thy 1 + cells constitutively display 
high levels of high affinity IL-2 binding sites, are not dependent upon antigen for IL-2 
responsiveness, but are strictly dependent upon exogenous IL-2 for viability and 
growth (Baker et a! . ,  1 979). In fact, the growth of these cells has been commonly 
used as a bioassay for IL-2. Thus, CTLL-2 offers a model system to study the 
growth factor dependent phases of T cell activation without confounding effects of 
antigen presenting cells or TCR triggering. The results of the studies described here 
provide evidence that inhibition of IL-2 dependent T cell growth by TGF� is not 
temporally associated with any major inhibition of IL-2R surface expression. 
However, inhibition of IL-2-induced synthesis of mRNA for various T cell associated 
molecules occurs in a matter of hours after TGF� addition, suggesting that intracellular 
transduction of the IL-2 stimulus or early genetic events triggered by IL-2 may be 
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points at which TGFp exerts an inhibitory effect on T cell growth. 
Results 
TGF{3 inhibits proliferative responses to lL-2. 
Treatment of CTLL-2 with TGFp resulted in dose-dependent inhibition of tritiated 
thymidine incorporation in response to rIL-2. Maximal inhibition of proliferation (70-
80%) was observed after addition of I ng/ml TGFp; half maximal inhibition was seen 
at 0.05 ng/ml (Figure 2 .0 1 ) .  To determine whether this growth inhibition could be 
overcome with greater amounts of IL-2, proliferation was also examined as a function 
of IL-2 concentration at a fixed dose of 5ng/ml TGFp. Control cultures of CTLL-2 
incorporated TdR essentially as a function of IL-2 dose, with maximal incorporation 
observed at 25U/ml IL-2, while incorporation dropped off at higher doses of IL-2, 
presumably secondary to overgrowth of the cultures. When TGFp was added to 
parallel cultures, the dose-response to IL-2 was flat even at the highest concentration 
of IL-2 (50U/ml), measured at 24 or 48h (Figure 2.02), indicating that DNA synthesis 
was significantly inhibited by addition of TGFp. To ascertain whether the TGFp­
induced inhibition of DNA synthesis was also reflected in suppression of cell growth, 
cells were treated with optimal concentrations of IL-2 ± TGFp and enumeration of 
viable cells was done. As shown in Figure 2.03, cell growth was not absolutely 
inhibited by TGFp but rather was reduced by approximately 50% in a time- and dose-
60 
61  
dependent manner. These results demonstrate that the effect of  TGF� on DNA 
synthesis was associated with inhibition of CfLL-2 mitosis in response to IL-2. 
These data were essentially confirmed by analysis of DNA content in cells that 
were treated for 24h with IL-2 alone, IL-2 + TGF�, or IL-2 + hydroxyurea. As 
shown in Figure 2.04, HU efficiently caused the accumulation of 95% of nuclei in 
GO/G1 as compared to 49% for TGF�-treated cells and 38% for controls treated 
with IL-2 alone. 
Effect of TGF� on the IL-2R 
The IL-2-dependent growth response of CTLL-2 is mediated by IL-2 binding 
to high affinity IL-2R sites (Malek and Ashwell, 1985). High affinity IL-2R 
binding sites are composed of three integral membrane proteins identified as IL-
2Ra (p55), IL-2R� (p75), and the most recently cloned IL-2Ry (p64) (Takeshita 
et al., 1992). We hypothesized that a reduction in the rate of proliferation and 
inhibition of cell cycle progression might result from a down-regulation of IL-2 
receptor expression on CTLL-2 treated with TGF�, as suggested by others 
(Ruegemer et al., 1990; Stoeck et al., 1989a; Kehrl et al., 1986b). To test this 
hypothesis, cultures were stimulated with 20U/ml IL-2 ± 1ng/ml TGF�. IL-2Ra 
surface peptides were stained with FITC-conjugated anti-IL-2Ra Ab, and fluores­
cence intensity was quantitated and analyzed by F ACS. At initiation of culture, 
cells were essentially 1 00% IL-2Ra+. Analysis of IL-2Ra mean fluorescence 
intensity (MFI) values on day 1 showed in most cases that a modest up-regulation 
of the IL-2Ra antigen level occurred when CTLL-2 were treated with IL-2 alone ; 
the cells also continued to score 100% IL-2Ra+ (Table 2.0 1 ). In TGF�-treated 
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cultures, although �93% of cells remained IL-2Ra+, MFI values averaged only 
66% that of controls on day 1 (Figure 2.05).  Peak IL-2Ra immunofluorescence 
after IL-2 alone was detected on day 1 and by day 2 after treatment, IL-2Ra 
levels declined slightly. In the presence of TGFj3, this decline was more marked, 
as MFI values for TGFj3-treated cells averaged only 44% that of controls on d2. 
After 3 days of culture with IL-2 + TGFj3, IL-2Ra surface staining was 
consistently lower than for cells treated with IL-2 alone (Table 2.01 and Figure 
2.06). 
To determine whether TGFj3 affected IL-2Ra at earlier times, CfLL-2 were 
treated with IL-2 ± TGFj3 and IL-2Ra expression was measured after 1, 3, 6, 12, 
and 24h. As shown in Figure 2.07, a time-dependent increase in the accumulation 
of IL-2Ra chains occurred in response to IL-2, but no affect of TGFj3 was seen 
until 24h, where TGFj3-treated cells demonstrated 40% less surface staining for 
IL-2Ra, as documented in other experiments shown above. 
Although TGFj3 modestly inhibited expression of IL-2Ra 24h after treatment, 
the overwhelming majority of cells were still IL-2Ra+ at this time. Therefore it 
seemed unlikely that growth inhibition at 24h could be due solely to limiting 
numbers of IL-2Rcr surface receptors. As other peptides are necessary for the 
assembly of functional IL-2R sites, we hypothesized that TGFj3 might be acting to 
limit IL-2 binding by other mechanisms. To simultaneously correlate changes in 
IL-2Rcr expression with IL-2 binding, cells were stained with both FITC-con­
jugated anti-IL-2Ra Ab and PE-conjugated IL-2-biotin. Cells demonstrated bright 
immunofluorescence with both stains, verifying that no significant competition 
occurred between these two reagents (Figure 2.08). When TGFj3 treated cells 
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were compared to controls at 24h, IL-2Ra levels and biotinylated IL-2 staining 
were reduced by 25 and 43%, respectively, as scored by MFI. At 48h (Figure 
2.09), when TGF,B-treated cells were compared to controls, IL-2Ra and 
biotinylated IL-2 staining were reduced by 73 and 75%, respectively. Thus, these 
results show that IL-2 receptor levels, as measured either by anti-IL-2Ra or by 
staining with biotinylated IL-2 ligand, were lower in groups treated with TGF,B, 
especially after 24h of treatment. TGF,B did not affect either IL-2Ra chain 
expression (Figure 2.07) or biotinylated IL-2 binding (data not shown) at times 
prior to 24h.  
Effect of TGF,B on IL-2-induced gene expression 
To determine whether TGFI3 affects IL-2-induced gene expression, we first 
examined the effect of TGFI3 on expression of mRNA for various T cell as­
sociated genes. In CfLL-2, we have found that intracellular levels of mRNA for 
IL-2Ra, IL-2R,B, c-myc, and the cytolytic granule associated molecule Granzyme B 
are tightly regulated by exposure to IL-2. Several days after feeding cells with IL-
2, these mRNA species are barely detectable and rise sharply (by 1 -3h) in 
response to fresh IL-2 exposure. Thus, the cellular response to IL-2, as measured 
by the accumulation of RNA molecules, is very rapid. As shown in Figures 2. 10-
2. 12, TGFI3 inhibited IL-2-dependent accumulation of mRNA for IL-2Ra, and IL-
2RI3, Granzyme B, and IL-4R by 75 %, 45-85%, 80%, and 55%, respectively at 
12h. Marked inhibition of these mRNA species was also seen at times as early as 
3h after TGFI3 treatment (Figures 2.10 and 2.12). In two experiments, one hour 
after treatment of CfLL-2 with IL-2 ± TGFI3, c-myc mRNA expression was also 
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inhibited by 43 and 55% as measured by Northern analysis (Figure 2. 13).  These 
data suggest that a variety of very early T cell responses to IL-2 are inhibited by 
concomitant treatment with TGFI3. 
TGFI3 is known to inhibit the expression of many genes in many different 
tissue types and treatment of lymphocytes for 24h with TGFI3 was shown to inhibit 
tritiated uridine incorporation by 50% (Bartlett et aI., 199 1 ).  Thus, the inhibition 
of IL-2-induced mRNA expression seen in the above Northern analyses might be 
specific for the genes examined, or alternatively, may be secondary to a general 
i nhibition of IL-2-dependent RNA synthesis. To determine whether TGFI3 
affected overall RNA synthesis in CfLL-2, CfLL-2 were treated with 20U/ ml IL-
2 ± 1ng/ml TGFI3 for 4 or 1 8h and then nuclei were harvested for in vitro run-on 
transcription. Newly synthesized RNA transcripts were isolated and the 
incorporation of 32p uridine triphosphate (UTP) was measured. Four hours after 
treatment with IL-2 vs. IL-2 + TGFI3, incorporation of 32x 106 and 16x 1 06 cpm 
(per 50x I 06 nuclei) were measured, respectively, demonstrating a 50% inhibition 
of RNA synthesis for cells treated with TGFI3. For nuclei harvested I 8h after 
addition of IL-2 vs. IL-2 + TGFI3, 32p UTP incorporation was 1 6.4x106 and 
7.2x 106 cpm respectively (per 5Ox106 nuclei), demonstrating 56% inhibition of in 
vitro RNA synthesis by nuclei from TGFI3-treated cells. The data from the 
Northern analyses and nuclear run-ons above demonstrate that TGFI3 has a 
negative regulatory effect on very early responses that are signalled through pre­
existing IL-2R sites which may be causally related to the inhibition of IL-2-
dependent DNA synthesis (Figures 2.01 and 2.02) and the production of new 
surface IL-2Ra chains (Table 2.02) seen at 24h. 
Discussion 
The control of cellular proliferation in multicellular organisms is a complex 
process. Proper functioning and homeostasis in epithelial, endothelial, and lymphoid 
tissues, for example, is dependent upon strictly regulated cellular proliferation, and 
therefore a precise balance between proliferative and anti proliferative signals must be 
maintained. Much progress has been made in elucidating the nature of the growth 
stimulatory factors involved, and the identification of such cytokines as epidermal 
growth factor, platelet derived growth factors, and interleukins such as IL-2 and IL-4 
and knowledge of their mechanisms of action attest to this fact. However, mechanisms 
by which inhibition of cell division (and thus avoidance of neoplasia) is achieved are 
only now being elucidated. 
Antiproliferative effects of TGF(3. 
A number of studies have shown that the transforming growth factors-� inhibit 
the proliferation of epithelial (Coffey et aI . ,  1 988), endothelial (Takehara et aI . ,  1 987), 
and lymphoid cell types (Kehrl et aI . ,  1 986b; Ruegemer et al . ,  1 990; Stoeck et aI . ,  
1 989a; Morris et  aI . ,  1 989; Wahl et  aI., 1 988) .  CTLL-2 cells are constitutively display 
an average of 4,000 high affinity and 40,000 low affinity IL-2R sites per cell (Robb et 
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a! . ,  1 984), and thus do not require antigenic stimulation for expression of IL-2 respon-
siveness. These cells therefore represent a useful system to study the anti proliferative 
effects of TGFp on IL-2-dependent T cell growth, without consideration of the 
possibly confounding effects of TCR triggering on this process. Our data demonstrate 
that as early as 24h after addition of TGFp, IL-2 driven proliferation of CTLL-2 cells 
was inhibited by 70-85%. Even though IL-2 could not overcome TGFp-dependent 
inhibition of DNA synthesis, neither the inhibition of thymidine incorporation nor cell 
growth was absolute, suggesting that the effect of TGFp was to modulate 
responsiveness to IL-2 rather than to completely block DNA synthesis or act as a 
cytotoxin. Differences in cell cycle progression were seen as early as 1 2h after TGFp 
treatment and over the ensuing 48h, CTLL-2 steadily accumulated as a G1 peak. In 
contrast, control cultures demonstrated normal cell cycle progression as indicated by an 
increased S phase fraction after IL-2 addition, prior to arrest in G 1 ,  presumably due to 
exhaustion of IL-2 supplies after 2 days' culture. These data demonstrate that TGFp is 
inhibitory to CTLL-2 proliferation and are congruent with other reports showing that 
TGFp-treated cells are blocked in the G1 phase of the cell cycle (Whitson and Itakura, 
1 992; Cross and Cambier, 1 990; Lin et a! . ,  1 987). 
The molecular details of TGFp-dependent inhibition of epithelial cell growth has 
been elegantly described. In Mv l Lu cells, progression through G1 into S phase 
requires the concerted action of numerous cellular proteins, including those encoded by 
the c-myc and retinoblastoma RB loci .  The presence of a phosphorylated form of the 
retinoblastoma gene product RB is required for progression to S phase and thereafter, 
RB returns to a dephosphorylated form. As TGFp was shown to inhibit progression of 
epithelial cells from G1 to S, it was hypothesized that TGFp may influence cell growth 
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via an effect on RB and/or on c-myc expression. Indeed, numerous studies have 
shown that TGF� prevented G1 progression by interrupting the appearance (Yan et aI., 
1992) or phosphorylation (Laiho et ai., 1990a; Whitson and Itakura, 1992) of RB in 
late G1 •  Inhibition of phosphorylation was accomplished by preventing the appearance 
of the serine-threonine kinase molecule responsible for the enzymatic phosphorylation 
of RB (Massague et ai., 1992) and TGF� also blocked the activity of H I  kinase and 
p34cdc
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kinase (Howe et ai., 1991). Other studies have addressed the relationship 
between TGF�, RB and c-myc. In keratinocytes that overexpress the 
underphosphorylated form of RB and in keratinocytes treated with TGF�, the 
expression of c-myc was prevented; in both cases, a common 23 basepair element up­
stream of c-myc was required for this inhibition of gene transcription (Pietenpol et ai., 
1991 ). 
Currently, it is uncertain whether similar mechanisms underlie growth inhibition 
in lymphoid cells. Kehrl et af. found that lymphocytes have high affinity TGF� 
surface receptors, that TGF� inhibited T (Kehrl et ai., 1986b) and B (Kehrl et ai., 
1986a) cell proliferation in response to IL-2, and further demonstrated that TGF� was 
produced by these cells during immunologic responses. These data suggested that 
TGF� may play an autocrine or paracrine role in the regulation of growth factor 
dependent proliferation of T lymphocytes. Although it is possible that TGF� inhibits 
the growth of normal T cells via interference with initial signals emanating from the 
TCR, such an effect would not fully explain the marked growth inhibition seen when 
TGF� is added to cultures of T lymphocytes that are polyc1onally stimulated with 
mitogenic lectins, which are thought to act by multivalently crosslinking numerous 
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surface structures. Furthermore, Lee and Rich demonstrated that TGFp stimulated IL-
2-independent proliferation of murine splenic T cells in response to anti-CD3 
stimulation (Lee and Rich, 1 99 1 ) . Thus, an inhibition of TCR signalling alone cannot 
account for data showing that TGFp inhibits IL-2-dependent T cell growth; 
consequently the investigation of anti proliferative effects of TGFp has focussed on 
growth factor receptor expression and signal transduction. 
1L-2Ra is slowly downregulated after TGF{3 treatment. 
Competence for IL-2-stimulated proliferation requires adequate surface densities 
of functional high affinity (HA) IL-2 receptor sites. In T cells, the limiting chain for 
formation of such HA sites is IL-2Ra and triggering of the TCR complex by 
antigenlMHC is sufficient for limited expression of IL-2Ra chains. Subsequently, IL-
21IL-2R interactions serve to amplify the expression of IL-2Ra levels further (Malek 
and Ashwell, 1 985 ;  Smith and Cantrell, 1 985;  Plaetinck et aI . ,  1 990). Although 
CTLL-2 cells are not dependent upon antigenic stimulation for competence, increases 
in IL-2Ra density are seen in response to IL-2 treatment. Similar to a previous report 
(Stoeck et aI., 1 989a), we found that TGFp inhibited the IL-2-induced rise in IL-2Ra 
levels and caused a more rapid fall in IL-2Ra expression at later time-points. Because 
the inhibition of IL-2Ra upregulation on day 1 was of small magnitude and because 
IL-2Ra density was high regardless of TGFp treatment, it seemed unlikely that the 
early inhibition of IL-2Ra upregulation was responsible for growth inhibition seen at 
24h. Results of IL-2 binding analysis were similar; minimal inhibition of the IL-2-
dependent upregulation of IL-2 binding sites was seen after TGFp addition. Again, 
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>90% of cells stained positive with the biotinylated IL-2 reagent in the presence or 
absence of TGFp. In summary then, TGFp partially inhibits the transient rise in IL-
2R density seen 24h after IL-2 treatment but TGFp does not markedly change the total 
quantitiy of surface IL-2 receptors or IL-2 binding at the time (24h) when growth 
inhibition can be first documented. These data are consistent with a site of action for 
TGFp at a point downstream of the IL-2IIL-2R interaction. We cannot, however, 
exclude the possibility that TGFp affects the affinity of IL-2R sites, as affinity cannot 
be measured using the methodology employed in these studies. Of note, in other IL-2 
responsive murine T cell lines (HT2 and CT6) TGFp interferes with proliferation 
without an effect on the affinity of IL-2 binding (Ruegemer et aI . ,  1 990). 
TGF{3 inhibits early genetic events induced by 1L-2 
At the time when inhibition of proliferation was documented (ie, 24h) IL-2R 
surface levels did not appear to be limiting. Therefore, the effect of TGFp on earlier 
IL-2-induced processes was investigated in greater detail by using early genetic 
responses as a convenient parameter to monitor rapid cellular responses to IL-2 and 
TGFp. Prior to addition of IL-2, mRNA for components of the IL-2R and for 
Granzyme B was barely detectable. By 3h after IL-2 addition, 4- to 1 0-fold increases 
in mRNA level were seen, suggesting that transcription was affected. These 
experiments demonstrated very early (by I and 3h) inhibition of the IL-2-induced 
upregulation of c-myc, IL-2Ra, IL-2RP, Granzyme B, and IL-4R mRNA by TGFp. 
Thus, TGFp similarly inhibited accumulation of mRNA from several non-linked loci 
rapidly after IL-2 treatment. One explanation for this observation could involve an 
effect of TGFp on IL-2R signalling. The biochemical sequelae of engagement of HA 
IL-2R by IL-2 are poorly understood, but recently more information has become 
available regarding early cytoplasmic and nuclear responses mediated through the 
cytoplasmic domain of IL-2Rp. Within 5- 1 5min, multiple protein substrates (ie. the 
tyr kinase p56iCk and the ser/thr kinase p72-74 Raf- l )  become enzymatically 
phosphorylated on tyr and serlthr residues (Horak et aI . ,  1 99 1 ;  Turner et a! . ,  1 99 1 ) . 
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By 1 0-30min, marked stimulation of c-jun, jun-B, c-fos, and c-myc protooncogene 
mRNA occurs in response to signalling through IL-2RP, and at least some of these are 
required for IL-2-induced S phase entry (Shibuya et a! . ,  1 992; Hatakeyama et a! . ,  
1 992). Therefore multiple points have been identified in IL-2R signal transduction 
that may be targets for TGFp. Ortaldo recently demonstrated that 1 6h preincubation 
with TGFp inhibited the tyr phosphorylation of mUltiple proteins in CD3- NK cells 
l 5min after treatment with high-dose ( 1 ,000 U/ml) IL-2 (Ortaldo et a! . ,  1 99 1 ), which 
supports the hypothesis that TGFp may inhibit T cell growth by an effect on events 
immediately triggered by IL-2 binding. Whether such findings are also true for T cells 
awaits further study. 
TGFp also affects the expression and/or activity of protooncogene products that 
function as DNA binding proteins. In this way, it is possible that TGFp may regulate 
RNA transcription from many distinct loci. It was shown that TGFp inhibited the 
expression of mRNAs encoding products such as albumin and transinlstromelysin, and 
some have found that these effects correlated with increased jun-B and fos-B mRNA 
expression (Ohtsuki and Massague, 1 992; Beauchamp et a! . ,  1 992). Kerr et at. demon­
strated a 1 0  basepair Fos binding element in the transin promotor which was required 
for TGFWs inhibitory effect. This element was also found in the upstream regions of 
other genes inhibited by TGFp including c-myc (Kerr et a! . ,  1 990). Further evidence 
7 1  
o f  regulation o f  transcription factor expression by TGFp stems from the finding that 
autoinduction of the TGFp gene in TGFp-treated lung carcinoma cells is mediated by 
the (Fos-Jun) AP- I complex (Kim et aI . ,  1 990). As more becomes known about the 
normal biochemistry of IL-2 receptor signalling of nuclear responses, the role of TGFp 
in modulating these processes can be further scrutinized. 
In summary, inferences that may be made based on these data are: 1 )  Reduced 
expression of IL-2R is probably secondary to inhibition of IL-2-dependent maintenance 
of IL-2Ra expression, rather than a direct cause of growth inhibition. 2) Decreased 
proliferation is likely a result of TGFp's effect on IL-2-induced gene expression in 
general and not simply an isolated effect on IL-2-induced proliferation related events. 
3) Sites that could formally be implicated as targets of the antiproliferative effect of 
TGFp include IL-2R transmembrane signalling, biochemical events in the cytoplasmic 
components of IL-2R signal transduction, and/or modulation of broadly acting factors 
(such as c-myc) which regulate the genetic response to IL-2. 
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Table 2 .0 1 : I L-2Ra expression in CTLL-2 cells treated with TGF�. CTLL-2 were 
treated with 20U/ml IL-2 ± I ng/ml TGF� for various periods prior to FACS analysis 
of IL-2Ra. 
IL-2 alone IL-2 + TGFB 
Exp # Day %+ MFIb 0/0+ MFI 
0 1 00 1 98 
1 00 444 1 00 
2 0 1 00 1 06 
1 1 00 9 1  1 00 
3 0 98 47 
1 1 00 1 76 1 00 
2 99 45 99 
4 0 97 1 76 
1 98 1 8 1  93 
2 97 1 58 84 
5 1 97 250 93 
2 95 1 00 46 
6 0 .5  1 00 461 1 00 
1 98 300 88 
2 98 246 67 
7 0 99 65 
2 1 00 4 1 9  99 
3 99 1 70 9 1  
4 1 00 1 1 2 83 
8 2 1 00 1 28 77 
• %C, Percent control=MFI of IL-2+ TGF� divided by MFI of IL-2 alone 
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Figure 2 .0 1 :  TGF� dose-dependent inhibition of proliferation. CTLL-2 cells were 
treated for 24h with 20U/ml IL-2 ± various concentrations of TGF�. Concurrently, 
cultures were treated with 37kBq of eH] TdR. TdR incorporation was measured and 
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Figure 2.02: TGFp inhibits proliferation of CTLL-2. CTLL-2 were treated with 
various concentrations of IL-2 ± 5nglml TGFp for 24 or 48h. For the final 24h of 
culture [3H]_ TdR was added and incorporation of this isotope was quantitated and 
expressed as the arithmetic mean (± S.D.) of quadruplicate determinations. rh IL-2, 
recominant human IL-2 
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Figure 2.03 : TGFp inhibits CTLL-2 growth. 1 )  Line graph: CTLL-2 cells were 
incubated with 20U/ml IL-2 ± I ng/ml TGFp and harvested at various times for 
enumeration of viable cells by hemocytometer after trypan blue treatment. Open 
squares, 20U/ml IL-2 alone; filled squares, IL-2 + I ng/ml TGFp. 2) Bar graph: In a 
different experiment, CTLL-2 were treated for 24h with 20U/ml IL-2 and various 
concentrations of TGFp (ng/ml) prior to counting viable cells. 
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Figure 2 .04:  Cell cycle analysis of TGFp-treated CTLL-2. CTLL-2 were treated with 
20U/ml IL-2 ± l ng/ml TGFp ± I mM hydroxyurea (HU) for 24h prior to cell lysis and 
staining of nuclei with propidium iodide. DNA fluorescence was then analyzed by 








Figure 2.05 : Effect of TGF� on IL-2Ra. Graphic representation of data in Table 
2 .02. 
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Figure 2.06: IL-2Ra expression falls late after TGF� treatment. CTLL-2 were treated 
with 20U/ml IL-2 ± Sng/ml TGF� for various days prior to F ACS analysis of IL-2Ra 
surface expression. IL-2Ra immunofluorescence data obtained from 1 0,000 cells are 
expressed on a four decade abscissa as a function of cell number (ordinate). Fresh 
cytokines were added on day 2 .  
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Figure 2.07: TGFp does not affect early expression of surface IL-2Ra.  CTLL-2 cells 
were harvested from culture 2d after previous IL-2 feeding and stimulated with 
20U/ml IL-2 ± 5ng/ml TGFp prior to F ACS analysis of IL-2Ra expression. Mean 
fluorescence intensity (LINES, left axis) was plotted as a function of time. Percent 
IL-2Ra positive cells (BARS, right axis) was also plotted for these samples. 
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Figure 2 .08 :  Coordinate expression of IL-2Ra and IL-2 binding (24h). CTLL-2 were 
treated for 24h with 20U/ml IL-2 (left panel) or IL-2 + l ng/rnl TGF� (right panel) 
prior to analysis. F ACS analysis after staining cells with FITC-conjugated Ab 
recognizing IL-2Ra (abscissa) and PE-labelled IL-2 (ordinate) is  shown. These data 
were subsequently analyzed and plots generated using Lysys computer software. 
88 
24h : 




Figure 2.09: Coordinate expression of IL-2Ra and IL-2 binding (48h). Cells from the 
experiment described in Figure 2 .09 above were analyzed at 48h. 
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Figure 2 . 1 0 : Northern analysis of CTLL-2, Experiment # 1 .  CTLL-2 were cultured for 
0, 1 2, or 48h with 20U/ml IL-2 in the absence (triangles) or presence (circles) of 
l ng/ml TGFp. The mRNA signal intensity (ordinate) from appropriately exposed 
autoradiograms was quantitated as described in Materials and Methods and plotted as a 
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Figure 2. 1 1 : Northern analysis of CTLL-2, Experiment #2. In this experiment, 
CTLL-2 were cultured for 0, 3, 6, 1 2, or 24, with 20U/ml IL-2 in the absence 
(triangles) or presence (circles) of 1 ng/ml TGFp. Northern analysis was performed 
and blots were sequentially probed with cDNA corresponding to A) Granzyme-B, B)  
IL-2RP, C) IL-4R, and D) p-actin. 
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Figure 2 . 1 2 : Autoradiogram data from Northern analysis of CTLL-2. This figure is a 
composite of data shown in Figures 2 . 1 0  (IL-2Ra from Experiment # 1 )  and 2 . 1 1  (IL-
2R�, Granzyme-B, �-actin, from Experiment #2). CTLL-2 were cultured for 0,  3 ,  6, 
1 2, or 24h with 20U/ml IL-2 in the absence ("-") or presence ( "+") of 1 ng/ml TGF�. 
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Figure 2 . 1 3 :  Northern analysis of c-myc expression. CTLL-2 cells were cultured for 
1 or 3h in IL-2 with (crosshatched bars) or without (solid bars) I ng/ml TGF. 
Northern analysis was performed as described in Materials and Methods and the 
arithmetic means of autoradiogram optical densities from two experiments were 
plotted. 
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Chapter 3 
Effect of TGFp on Morphologic and 
Phenotypic Characteristics of T Lymphocytes 
Introduction 
There is a great deal of interest in the effects of TGFp on lymphocyte growth and 
differentiation, and numerous reports of TGFp having stimulatory and inhibitory 
effects on differentiation in lymphoid compartments have recently emerged. TGFp 
inhibited LPS-stimulated B cell growth and secretion of most Ig isotypes. In contrast, 
under the same condition, TGFp caused preferential isotype switching to IgA resulting 
in a 5- 1 0  fold enhancement in the amount of IgA secreted. In contrast, secretion of all 
other Ig isotypes was decreased (Coffman et aI., 1 989; Lebman et aI . ,  1 990a; Kim and 
Kagnoff, 1 990) . Also, surface expression of MHC class II antigens on LPS-stimulated 
B cells was shown to be modestly up-regulated by TGFp (Cross and Cambier, 1 990). 
Finally, TGFp inhibited growth of CD4+ T cells stimulated with Con-A while favoring 
the maturation of cells with a Thl cytokine secretion profile (Swain et aI . ,  1 99 1 ). 
Taken together, these data provide evidence that TGFp has multiple regulatory effects 
on lymphocytes, and suggest that in addition to inhibition of cell growth, differen­
tiation of lymphoid cells may be influenced by low concentrations of this cytokine. 
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Indeed, this probably reflects a more generalized phenomenon--that cell growth must 
be halted for functional differentiation to occur. 
While studying the anti-proliferative effect of TGF� on the CTLL-2 murine T cell 
line, we noted striking morphologic and phenotypic changes in these cells after 
treatment with TGF�. In this chapter, we provide evidence that TGF� up-regulates 
CD8 expression in CTLL-2 cells, and we also show that TGF� has a similar effect on 
normal, immature thymocytes. These data suggest a role for TGF� in thymocyte 
differentiation, and these models offer a way to study the molecular regulation of CD8 
gene expression. 
Results 
TGF{3 treatment results in morphologic and phenotypic changes in T cells and 
increased substrate adherence. 
In addition to the growth inhibition described in Chapter 2, TGFp markedly 
altered the morphology of CTLL-2 cells. As shown in Figure 3 .0 I ,  compared to the 
uniformly round appearance of CTLL-2 grown in IL-2 alone, many of the cells 
exposed to IL-2 + TGFp took on a stellate and spread morphology. Differences in 
morphology were also documented by F ACS analysis, in that TGFp-treated cells 
demonstrated reduced forward angle light scatter (FSC), indicative of a smaller cell 
size. Side angle light scatter (SSC), which reflects intracellular complexity, was 
essentially unaffected by TGFp treatment (Figures 3 .02) .  
In addition to the altered morphology described above, a large percentage of 
CTLL-2 exposed to TGFp became firmly adherent to the plates, requiring vigorous 
pipetting with ice-cold media for efficient harvest; cells which received IL-2 alone 
were non-adherent. To quantitate this phenomenon, nonadherent cells were removed 
by centrifugation and MTT (tetrazolium) reagent was used stain viable cells remaining 
in the adherent population. Reduced MTT was then solubil ized and the optical density 
of cell Iysates was measured. As with 3H-thymidine incorporation (Figure 2 . 0 1 ), a 
1 0 1  
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TGF� inhibited cell growth over 24h (Figure 3 .03). Simultaneous analysis of adherent 
cells demonstrated a TGF�-dose dependent increase, with plateau levels of adherence 
(50-60%) essentially being reached at 5nglml of TGF�. When the kinetics of 
adherence were investigated, maximal adherence was seen at 24h (Figure 3 .04) . 
The requirements for T cell adhesion in response to TGF� were investigated by 
first determining whether fetal calf serum (FCS) was required for the effect. In the 
absence of FCS, no increased adherence (above background levels seen in cells 
cultured in IL-2 alone) was detected in response to TGF� (Figure 3 .05). However, a 
direct relationship was seen between the concentration of FCS and adherence of 
CTLL-2 measured after 24h of culture in TGF�. Of the enumerable biochemical 
components contained in FCS, several peptides have been shown to be important for T 
lymphocyte-substrate adhesion. Among these, fibronectin and vitronectin are 
extracellular matrix components for which T cells express specific receptors of the 
integrin family. We next sought to determine whether CTLL-2 cells, incubated in the 
absence of FCS, would adhere to plates when fibronectin (FN) was added in purified, 
soluble form to the medium. Adhesion in response to TGF� was not seen when FN or 
control proteins were added (Figure 3 .05). Since the repeating RGDS motif on 
substrate peptides is recognized by �-subunits of numerous heterodimeric integrin 
receptors, we next questioned whether the TGF�-dependent adherence of CTLL-2 
could be antagonized by addition of soluble RGDS sequences. As seen in Figure 3 .06, 
adherence was reduced to baseline when 1 0  or 50flg/ml RGDS was added to groups 
that received a suboptimal concentration of FCS ( 1  %). The control tetrapeptide RGES 
was without effect on adherence. 
To determine whether TGF� was triggering other surface phenotypic changes in 
1 03 
CTLL-2, we examined the expression of T lymphocyte surface markers. Figure 3.07 
represents a profile of expression of various surface determinants 24 or 48h after 
treatment with IL-2 alone or IL-2 + TGFp. The expression of Thy l ,  CD3, CD4, 
uPTCR, y8TCR, LFA- I ,  NK l . l ,  Pgp- I (CD44), and HSA were essentially unaffected 
by TGFp treatment. TGFp-treated cells demonstrated reduced IL-2Ru levels. In 
some experiments, there were modest elevations in ICAM- I levels. Most striking, 
however, was the induction of high levels of CD8u (Lyt2 antigen) expression in a 
distinct subpopulation of TGFp-treated CTLL-2. During routine passage, less than 
1 0% of CTLL-2 cells were CDSu\ whereas 20 to 40% of cells expressed this antigen 
when treated with IL-2 + TGFp. Notably, the proportion of CDSu+ cells was not 
different for adherent versus non-adherent TGFp-treated cells (Figure 3 .0S). To 
determine whether the CDSu+ cells differed morphologically from CDSu' cells, FSC 
and SSC as a function of CDS expression were examined. As shown in Figure 3 .09, 
the CDS+ cells were homogeneously distributed throughout the population, with respect 
to cell size (FSC) and cytoplasmic complexity (SSC). To determine whether the CDS+ 
and CDS' populations of TGFp treated CTLL-2 differed with respect to any other 
surface markers, cells were stained for CDSu and for IL-2Ru, LFA- I ,  Thy- I ,  ICAM­
I ,  and CDSP (Figure 3 . 1 0). For most markers, CDSu+ cells were not different from 
CDSu' cells, with both subpopulations expressing identical levels of these other surfacE 
antigens. The only difference between CDSu+ and CDSu- subsets was regarding 
CDSP expression, where it was found that only the CDSu+ subpopulation was capable 
of CDSP expression (Figures 3 . 1 0D). On average, 20% of CDSu+ cells also expressed 
the CDSP antigen. 
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Dose response and kinetics of CD8 expression induced by TGF{3. 
Various concentrations from 0.01  to 5 ng/ml of TGF� were titrated into CTLL-2 
cultures. After 24h, dose-dependent increases in expression of CD8a and CD8� were 
seen, with plateau levels of both chains (40% and 8%, respectively) essentially being 
reached by the addition of 0.5 ng/ml TGF� (Figure 3 . 1 1 ) . Thus, 1 nglml TGF� was 
selected for subsequent experiments. Similar effects on CD8 were seen when I ng/ml 
recombinant human TGF� (Biomedical Technologies, Inc., Stoughton, MA) was used 
(data not shown), thus excluding the possibility that the porcine platelet derived TGF� 
contained contaminating factors that were responsible for the effect on CD8 
expression. The relationship between CD8a and CD8� expression in response to 
TGF� was similar in all experiments, with only 20-40% of CD8a+ cells also express­
ing CD8�. Cells expressing CD8� without CD8a were not detected under any culture 
conditions. 
The kinetics of TGF�-induced CD8 expression were analyzed over a four day 
period. At culture initiation, which was 2 days after the last addition of IL-2, ::::5% of 
CTLL-2 cells  were CD8a+ (Figure 3. 1 2). When treated with IL-2 alone, no sustained 
increase in CD8 expression was noted. However, in the presence of TGF�, 30-40% of 
the cell s  rapidly became CD8a+ by 24h and maintained their expression during the 4-
day culture. When expression of this antigen was analyzed in cells cultured long-term 
in IL-2 + TGF� ( 1 0- 1 4d), again 30-40% of cells were CD8a+. Similar to the data 
presented in Figure 3 . 1 1 ,  1 0-20% of cells treated with TGF� during the time-course 
became CD8�+, CD8� was only detected on a subset of CD8a+ cells, and maximal 
expression of the � chain routinely lagged 24-48h behind CD8a (Figure 3 . 1 3). 
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Appearance of CD8+ cells is neither secondary to selective outgrowth of a minor CD8+ 
subset nor a result of growth inhibition. 
A rise in the percentage of CD8+ cells might result from de novo expression of 
the determinant in cells previously negative for this marker, and/or from selective 
survival or outgrowth of cells expressing this antigen. After 30% of cells became 
CD8+ by 24h, the percentage did not increase further over time beyond this plateau 
value. Thus, it seemed unlikely that the increase in CD8+ cells could occur by a 
selective growth advantage of CD8+ cells in TGFp. To test the alternate possibilities 
more directly, experiments were performed to determine whether cell growth was 
required for CD8+ cells to appear in TGFp-treated cultures. CTLL-2 were treated for 
24h with IL-2 ± TGFp ± hydroxyurea (HU, I mM; at this concentration, HU inhibited 
proliferation and cell cycle progression by >95%, shown in Figures 3 . 1 4  and 2 .04, 
respectively). The results of two separate experiments showed identical proportions of 
CD8+ cells in cultures treated with TGFp in the presence (4 1 %) or absence of HU 
(4 1 %) .  Thus, these data demonstrate that CD8 can be induced by TGFp in the virtual 
absence of cell division. 
To determine whether CD8-bearing cells were selectively resistant to the growth 
inhibiting effect of TGFp, CD8 was induced in CTLL-2 by three days' culture in IL-2 
+ TGFp, after which time CD8+ and CD8- cells were separated by "panning."  Both 
subsets were then re-cultured in IL-2 ± TGFp for an additional 2 days prior to 
performing cell counts. The growth of CD8+ and CD8- cells re-cultured in IL-2 alone 
was similar, with cell recoveries of 1 68% and 1 86%, respectively. The growth of both 
groups was inhibited by I ng/ml TGFp added during re-culture, with recoveries of 48% 
and 76% for CD8+ and CD8- respectively. Thus, CD8+ cells were, if anything, more 
sensitive to the anti-proliferative effect of TGFp, suggesting again that selective 
outgrowth or survival of this subpopulation would not occur. 
1 06 
CD8 expression on cells in TGFp-treated cultures may be a specific response to 
this cytokine, or could merely be secondary to growth inhibition. To distinguish 
between these two alternatives, CTLL-2 cells were treated for 24h with 1 )  IL-2 alone, 
2) IL-2 + HU, or 3) IL-2 + TGFp. The percentage of CD8+ cells for these three 
groups was 9, 1 1 , and 30%, respectively; similar results were obtained in three such 
experiments. Thus, despite complete inhibition of growth, the addition of HU alone 
caused no change in expression of CD8 as compared to cells cultured in IL-2 alone. 
TGF{3 is required for maintenance of CD8+ phenotype. 
To determine whether CD8 expression was a stable phenotypic change, CTLL-2 
were first treated with IL-2 and TGFp for three days, then washed free of TGFp and 
re-cultured in IL-2 alone or IL-2 + TGFp. As shown in Figure 3 . 1 5, when re-cultured 
in IL-2 alone, the percentage of CD8+ cells declined over the next four days, as 
compared to cells re-cultured in IL-2 + TGFp, where the percentage of CD8+ cells 
doubled. This experiment suggested that continued CD8 expression was dependent on 
the presence of TGFp. To examine the stability of TGFp-induced CD8 expression 
more directly, CTLL-2 were cultured for three days in IL-2 + TGFp, washed, and 
separated into CD8+ and CD8· subsets by panning. Each fraction was then re-cultured 
for an additional eight days in IL-2 ± TGFp. CD8 expression in the CD8-enriched 
group remained high in IL-2 + TGFp but dramatically declined in IL-2 alone (Figure 
3 . 1 6), indicating that in most of the separated CD8+ cells, CD8 expression required the 
continuous presence of TGFp. Interestingly, the group depleted of CD8+ cells did not 
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express this determinant when treated with IL-2 + TGF� for an additional eight days. 
Induction of CD8 expression by TGF{3 requires RNA synthesis and correlates with 
increased steady-state levels of CD8cd{3 mRNA. 
To determine whether TGF�-induced CD8 expression was dependent on new 
RNA synthesis, CTLL-2 were incubated for 8h in IL-2 ± TGF� in the presence or 
absence of 51-lg/ml actinomycin-D. The viability of cells treated for 8 hours with 
medium alone, EtOH vehicle, and actinomycin-D was 95%, 78%, and 7 1 %, 
respectively. Beyond 8h, the viability in actinomycin-D declined rapidly, and FACS 
data could not be interpreted. F ACS analysis at the 8h timepoint showed that in IL-2 
alone, 7% of cells were CD8+. Treatment with IL-2 + TGF� in the absence or 
presence of the EtOH vehicle resulted in 1 7  and 1 8% CD8+ cells, respectively, 
compared to only 4% for cells treated with IL-2 + TGF� + actinomycin-D. Such 
inhibition of TGF�-induced CD8 expression by actinomycin-D was consistently seen 
in three separate experiments (Table 3 .0 1 ). These data suggested that new RNA 
synthesis was required for the increased percentage of CD8+ cells in TGF�-treated 
cultures. 
The hypothesis that TGF� treatment induced the de novo expression of CD8 was 
also tested using Northern blot analysis. As shown in Figure 3 . 1 7, CD8u and CD8� 
mRNA accumulated rapidly in response to TGF� and IL-2. Only transient, low-levels 
of CD8 mRNA were detected in response to IL-2 alone, in agreement with the F ACS 
data. However, in the presence of TGF�, heightened levels of both mRNA species 
detected with the CD8u cDNA ( 1 . 7 and 3 .5  Kb) were seen as early as 3-6h after 
treatment with TGF�. By 1 2-24h, 4- to 5-fold higher steady-state CD8u mRNA levels 
l OS 
were seen in TGFp-treated cells, as compared to cells cultured in IL-2 alone (Figure 
3 . 1 S) .  Again, consistent with the F ACS data, CDSu message peaked more rapidly (by 
1 2-24h) than CDSP, which was still increasing at 24h after addition of TGFp. In most 
cases, mRNA for CDS fell to baseline by 4Sh. Upon re-addition of fresh IL-2 and 
TGFp, a striking rise in mRNA for CDSu was seen. When comparison was made 
between CDSu mRNA levels 3h after initial treatment with IL-2 + TGFp and 3h after 
re-addition of fresh IL-2 + TGFp to cultures that had been previously treated for 4Sh 
with IL-2 + TGFp, a 55-fold increase in signal intensity was seen (Figure 3 . 1 9) .  The 
mechanism by which this enhanced "secondary response" occurs is currently being 
investigated. These data clearly demonstrate that the appearance of CDS mRNA in 
this cell line is tightly coupled to treatment with TGFp. To control for equal RNA 
loading, ethidium bromide stained gels were inspected and p-actin was also probed. 
Equivalent I SS and 2SS rRNA bands were seen for all timepoints. 
To further defme the response of CDS mRNA to TGFp, cells were treated with 
20U/rnl IL-2 and various doses of TGFp. Analysis of CDSu and CDSP mRNA 
showed increasing accumulation of these molecules up to the highest dose of TGFp 
used (5ng/ml). Thus, no plateau was seen over the dose interval used (Figure 3 .20). 
Interestingly, when this blot was re-probed with a p-actin specific cDNA, a TGFp­
dose dependent stimulation of this message was observed, rising approximately 5-fold 
above control at this 24h timepoint. When ethidium bromide stained rRNA bands 
were compared between lanes, equal loading of total RNA was confirmed. 
CTLL-2 are non-cytolytic. 
In general, when cellular differentiation programs are activated, cells cease to 
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proliferate, while changes in morphology and phenotype are commonly observed. 
During antigen-dependent sensitization of CDS+ T lymphocytes in the presence of IL-
2, maturation of cytolytic function occurs. As TGFp-treated CTLL-2 demonstrated 
some characteristics of differentiating cells, it was important to ascertain whether 
differentiation of functional characteristics also occurred in response to TGFp. CTLL-
2 were treated with TGFp for 4Sh and then harvested for cytotoxicity assay. Neither 
nonspecific nor anti-CD3 redirected killing of the Fc receptor bearing PS 1 5  
mastocytoma was seen with TGFp-treated CTLL-2 effectors; CD3+, PHS-5-specific 
CTL clones that were used as positive controls appropriately lysed targets (Figure 
3 .2 1 ) . In light of the inhibition of Granzyme B by TGFp, and the predominant lack of 
surface CD3rrCR on CTLL-2, this result was not unexpected. 
Intracellular signalling involved in TGF(3-dependent CDS expression. 
Currently, intracellular signalling mechanisms by which mammalian cells respond 
to TGFp are incompletely understood. We sought to determine whether PKC or 
intracellular calcium played a role in the CDS response to TGFp in CTLL-2 cells. We 
hypothesized that if TGFp triggered CDS expression via a PKC- or calcium-dependent 
pathway, incubating cells with PDBu or ionomycin (Io) may also result in CDS 
expression. Cells were incubated with IL-2 ± PDBu ± 10 for 24h prior to CDS 
immunofluorescent analysis. We confmned that PDBu had some effect on the cells by 
measuring a nominal increase in cell size of the populations exposed to PDBu. 
However, as shown in Table 3 .02, CDS expression was not seen when cells were 
treated with PDBu (lOOnM or 1 ,000 nM) or PDBu + 10 ( 1 0-6 M), indicating that 
neither PKC activation nor intracellular calcium elevation could replace the TGFp 
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signal. 
Although direct PKC activation was not sufficient for CD8 expression, the 
possibility that PKC was necessary for this effect still existed. It was shown that 
incubation of CTLL-2 with 500ng/ml (990nM) PDBu for 48h resulted in rapid and 
sustained depletion of PKC (Redondo et aI . ,  1 988). Therefore, CTLL-2 were incu­
bated with IL-2 ± 1 ,000 nM PDBu for 48h then washed and cultured ± PDBu ± TGFp 
for an additional 24h prior to CD8 analysis (washing T cells in wann medium reverses 
effects of PDBu on T lymphocytes (McCrady et al., 1 988)). In cells depleted of PKC, 
CD8 expression only reached 50-60% of control level in response to TGFp, suggesting 
that PKC indeed played a role in optimal signalling of CD8 expression. 
TGF{3 does not increase CD8 expression in mature T cells or other T cell lines. 
Next, we sought to determine whether CD8 expression can also be manipulated by 
TGFp in mature splenic T lymphocytes. Using a well established model of cytotoxic 
T lymphocyte generation in response to tumor cells, we showed in Chapter 1 that 
tumor-sensitized T cells from P8 1 5  tumor immune mice generate cytotoxic T cells 
when incubated in vitro with P8 1 5  tumor cells and that this response was inhibited by 
TGFp. Splenocytes from P8 1 5-bearing mice were stimulated with P8 1 5  tumor cells 
and cultured in complete medium ± 2.5 or 5 ng/ml TGFp for a period of 7 days. As 
shown in Table 3 .04, CTL generation was markedly inhibited in TGFp-treated groups. 
However, no change in the proportions of CD4- or CD8-positive cells was seen. 
Additionally, no change in the CD8 fluorescence intensity was detected in cells treated 
with TGFp (Table 3 .04 and Figure 3 .22). To further assess the effect of TGFp on 
CD8 expression in normal, mature T cells, splenocytes from C57BLl6J mice were 
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harvested and stimulated to grow with soluble anti-CD3 ( l 45-2C I I )  and cultured in 
20U/ml IL-2 or IL-2 + 5nglml TGF�. After 2 days' culture, cell numbers in both 
groups had tripled and the expression (percent positive @ MFI) of CD8a, CD8�, and 
IL-2Ra was assayed by F ACS. For cells cultured in aCD3 + IL-2, results were: 
CD8a=43% @ 279, CD8�=45% @ 507, IL-2Ra=55% @ 1 88 .  For cells treated with 
aCD3 + IL-2 + TGF� results showed: CD8a=4 1 @ 350, CD8�=42% @ 460, IL-
2Ra=46% @ 234. We also determined that the expression of CD8 in CD4-CD8+ 
P8 1 5-specific CTL clones was not altered by TGF�. When GD 1 1 . 1  ° cells were 
treated with 20U/ml IL-2 or IL-2 + 5nglml TGF�, cells from both groups stained 
>90% CD8a+ and mean CD8a immunofluorescence was 1 2.6 and 1 3  for these two 
groups respectively. These data demonstrate that expression of CD8 in populations of 
mature, CD4+ and/or CD8+ cells was not changed by TGF�. 
To determine whether other CD8- cell lines were capable of CD8 expression in 
response to TGF�, EL-4, BW5 147, and an independent CTLL-2 line obtained from the 
American Type Culture Collection were tested. When treated with IL-2 ± TGF�, de 
novo CD8 expression was only noted in CTLL-2 derived from ATCC and the CTLL-
2.TH line used throughout this manuscript (data not shown), demonstrating that 
independently maintained CD8-negative CTLL-2 lines respond to TGF� by CD8 
expression, and that these cells may represent a unique cell line model of this 
phenomenon. 
Effect of TGF{3 on CD8 expression in un fractionated thymocytes. 
We sought to determine whether TGF� would also induce CD8 expression in 
normal murine thymic T lymphocytes. Thymocytes from 1 2-week-old DBN2 mice 
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were stimulated by overnight culture in PDBu and 10 and then cultured in IL-2 alone 
or IL-2 + TGFp. As previously described (Ellingsworth et ai., 1 9S5) TGFp had a 
marked antiproliferative effect on thymocytes (Figure 3 .23) .  To determine whether 
CDS expression was affected by TGFp in this population, F ACS analysis of CD4, 
CDSa and CDSP was performed. Prior to culture, thymocytes were S% CD4'S-, (DN, 
double negative) 5% CD4+S', 2% CD4-S+, and S6% CD4+S+ (DP, double positive) 
(Figure 3 .24A). When cell surface phenotypes were compared at day 2 (data not 
shown) and day 4, it was noted that in both treatment groups the proportion of DP 
cells had dropped markedly (Figure 3 .24B, C). CD4 expression was similar for 
controls and TGFp-treated thymocytes. However, the percentage of CDS+ cells de­
creased when thymocytes were cultured in IL-2 alone, with 24% of IL-2-treated 
thymocytes being CDS+ on culture day 4 (Figure 3 .24B). In contrast, more than twice 
as many (56%) CDS+ cells were detected in cultures treated with IL-2 + TGFp (Figure 
3 .24C), and approximately SO% of these CDS+ cells were CD4-CDS+. Thymocytes 
treated with IL-2 + TGFp also demonstrated brighter CDSa fluorescence, with an MFI 
of 723 compared to 334 in IL-2 alone. Enhanced CDSP expression was also seen in 
IL-2 + TGFp-treated cultures, with 40% (MFI=223) of cells CDSP+ compared to 2 1  % 
(MFI= 1 36) in IL-2 alone. Notably, thymocyte growth and viability in this culture 
system required exogenous IL-2, and enhanced CDS surface expression was not seen 
when thymocytes were cultured in TGFp alone. The enhancement of surface CDS 
expression in thymocytes treated with IL-2 + TGFp also correlated with 2- and 5-fold 
increases in CDSa mRNA levels at I S  and 4Sh, as compared to thymocytes treated 
with IL-2 alone (Figure 3 .25). These data indicate that treatment with IL-2 + TGFp 
resulted in enhanced de novo CDS surface and mRNA expression in cultures of 
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unfractionated, normal thymocytes as compared to cultures treated with IL-2 alone. 
Effects of TGF{3 on double negative thymocytes. 
The DN thymocyte subset contains cells that can directly give rise to CD3'CD4'8+ 
cells, which are thought to give rise in tum to the DP subpopulation (MacDonald et 
aI . ,  1 988 ;  Guidos et al . ,  1 989; Shortman et aI . ,  1 988;  Nagamine et aI. ,  1 99 1 ;  Tatsumi 
et al . ,  1 990; Nikolic-Zugic et aI . ,  1 989; Nikolic-Zugic and Bevan, 1 988) .  To 
determine whether TGFp was influencing CD8 expression in immature thymocytes, 
DN cells were isolated and then distributed into four treatment groups prior to being 
pulsed with PDBu + 10:  1) medium alone, 2) IL-2, 3) TGFp, and 4) IL-2 + TGFp. 
Surface markers were analyzed by immunofluorescence over 12 days of culture. At 
culture initiation, <7% of cells stained positive for either CD4 or CD8u. Substantial 
cell growth occurred only in cultures containing IL-2. Regardless of treatment, <2% 
of cells were CD4+ at any timepoint (Figure 3 .26). Less than 1 3% of cells cultured 
with IL-2 alone were CD8+ on day 2, whereas 30% of cells treated with IL-2 + TGFp 
were CD8+ (Figure 3 .26 and Table 3 .05). As with CTLL-2 cells, a clearly identifiable 
and strongly CD8+ subpopulation emerged only in cultures treated with IL-2 + TGFp, 
and this subpopulation demonstrated a dramatic increase in CD8 fluorescence intensity, 
with MFI values of 295, 507, and 7 1 6  on days 2, 4, and 6, respectively. In contrast, 
the proportion of cells expressing CD8 was constant in cultures that received IL-2 
alone, with a maximal MFI of only 490 on day 6. For comparison, the MFI of CD8 
on normal DBN2 double positive thymocytes was 1 300. After initial expression, the 
proportion of CD8+ cells in cultures with IL-2 + TGFp remained approximately 30% 
throughout the 1 2  day culture period. DN thymocytes cultured in medium alone or 
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TGF� without IL-2 were 5 and 1 0% CD8+, respectively. 
TGF� also inhibited the proliferation of DN thymocytes stimulated with phorbol 
ester and ionophore. Thus, as with CTLL-2, the observed increase in the proportion of 
CD8+ cells might have resulted either from de novo expression of CD8 in previously 
negative cells, or from selective growth or survival of residual CD8+ cells in the DN 
cell preparation. In our experiments, TGF� inhibited the growth of DN thymocytes by 
40% during 4 days in culture. During this period, the percentage of CD8+ cells in­
creased from <2% to 30%, and the total cell number rose by 1 6-fold. Therefore, the 
absolute number of CD8+ cells increased by >240-fold during 4 days in culture. Thus, 
CD8+ cells present on day I would have had to divide every 9 hours to achieve these 
results by growth alone, which is an unlikely possibility. To determine directly 
whether cells in the CD8 SP thymic subpopulation were capable of such growth, CD8 
SP cells were isolated from murine thymi and stimulated with PDBu + 10 + IL-2 ± 
TGF�. With or without TGF�, CD8 SP thymocytes had a doubling time of 22h and 
actually grew more slowly than DN cells (doubling time= 1 8h) . Thus, selective 
outgrowth of CD8+ contaminants present on day 0 was unlikely under these conditions. 
An increased proportion of CD8+ cells might also have been seen if the replication 
rate of CD8+ cells emerging in TGF�-treated cultures was greater than that of DN 
cells. However, proliferation of DN cells and CD8 SP cells positively selected after t 
days in culture with IL-2 + TGF� were not significantly different when re-cultured in 
IL-2 + TGF� (Table 3 .06). Taken together with the results described above, these 
data demonstrate that, as with the CTLL-2 line, the emergence of a CD8+ population 
from DN thymocytes cannot be attributed to the selective outgrowth or survival of 
CD8+ cells. 
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To characterize further the subpopulation of DN thymocytes that became CD8+ in 
response to TGFp, dual parameter analysis was performed with antibodies specific for 
Thy 1 .2 or monomorphic determinants on either ap- or y8-TCR. Regardless of TGFp 
treatment, ::::,95% of all cells remained Thy 1 .2+ for the duration of the culture. Sixty 
percent of CD8+ cells were TCRJCD3-, demonstrating that the major effect of TGFp 
was to promote the appearance of TCRJCD3-CD4-CD8+ T cells (Figure 3 .27). Even 
after 1 2  days in culture, these CD8+ cells did not express increased levels of CD3 or 
CD4, indicating that further maturation did not occur. 
Discussion 
CD8, a novel target for TGF{3 action. 
After treatment of CTLL-2 cells with TGFp and IL-2, 30% of cells became 
CD8a\ and CD8P was detected only on CD8a+ cells. As CD8 expression was not 
seen when either TGFp or IL-2 were added alone, it is possible that either a 
synergistic relationship exists between these two cytokines, or, as IL-2 is necessary for 
viability of these cells, the absence of CD8 expression in response to TGFp alone 
might be explained by the fact that most CTLL-2 are dying after 24h without IL-2. In 
this model, CD8 surface expression was tightly coupled with TGFp exposure, with 
CD8 surface levels falling rapidly after removal of the cytokine. Interestingly, when 
CD8+ cells  were removed from TGFp-treated CTLL-2 cultures, the remaining CD8-
cells could not express the CD8 antigen even after prolonged culture in TGFp 
demonstrating that not all CTLL-2 were sensitive to this effect of TGFp; this may 
suggest heterogeneity in this CTLL-2 clone and perhaps a finite number of non­
renewable CD8 precursor cells existed in the population before TGFp treatment. It 
should be noted that, although none of the CD8- cells (that were panned from TGFp­
treated cultures) expressed CD8 when subsequently cultured with TGFp, these cells 
were growth inhibited by TGFp to a similar degree as CD8+ cells. However, it is also 
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possible that other mechanisms, such as secretion of soluble CD8 peptide (Norment et 
al . ,  1 989), or non-uniform distribution of TGF� receptor(s) may account for the fact 
that only a portion of cells in this CTLL-2 line expressed surface CD8 antigens in 
response to TGF�. In this regard, it is possible that the different types (I, II, and III) 
of TGFJ3 receptor have distinct, unshared functions (ie.  CD8 expression vs growth 
inhibition) and the expression of these receptors may be regulated independently. 
In our studies, treatment of CTLL-2 cells with TGF� also resulted in rapid growth 
inhibition concurrent with an increase in the proportion of CD8+ cells, whereas inhibit­
ing CTLL-2 growth with HU caused no significant change in CD8 expression. Thus, 
we can conclude that the increased CD8 expression was not merely a side-effect of 
inhibiting growth. It might have been argued that we did not see increased CD8 
expression after HU treatment because some other processes required for this to occur 
were inhibited or because the cells did not survive long enough in the presence of HU. 
However, CTLL-2 viability was maintained for two days after addition of HU, and 
CD8 expression was induced by TGF� in HU-treated cells within 24h, which also 
demonstrates that the increased number of CD8+ CTLL-2 cells was not a result of 
selective growth of a CD8+ subset in the presence of TGF�. 
Although expression of CD8a/� polypeptides must depend in part upon RNA 
transcription, the relative contributions of transcriptional and post-transcriptional 
mechanisms to the regulation of CD8 are unclear. It was reported that intracellular 
CD8� peptide levels are controlled at the mRNA level, although surface expression of 
CD8� is also regulated by post-translational mechanisms (Parnes, 1 989). Wilkinson et 
aI. , using a lymphoma model, showed that CD8a mRNA increased when protein 
synthesis was inhibited (Wilkinson et ai . ,  1 99 1 ). No change in transcriptional rate was 
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detected, suggesting that post-transcriptional mechanisms were responsible for the 
increased CD8 mRNA level. Only a transient shift in the peak CD8 immunofluo­
rescence was detected in those cells. In contrast, our studies using the non-neoplastic 
CTLL-2 line demonstrated the emergence of a discrete CD8+ subpopulation as long as 
TGFp was provided. We are currently in the process of determining the role of labile 
regulatory proteins in TGFp-dependent CD8 expression in CTLL-2. 
Routinely, less RNA is recovered per cell after treatment of CTLL-2 with IL-2 + 
TGFp for > 1 2-24h. Thus, the augmentation of CD8 mRNA level was a specific effect 
of TGFp, and steady-state levels of other genes, such as Granzyme B and IL-2R, were 
decreased in the same populations of TGFp-treated cells  (Figure 2 . 1 1 ) . Thy- l 
immunofluorescence was unchanged by TGFp treatment, indicating that indiscriminate 
down-regulation of other pre-existing surface antigens was not occurring. In CTLL-2, 
TGFp-dependent CD8 surface expression was sensitive to Actinomycin-D, which 
demonstrated that new CD8 expression required RNA synthesis. By Northern analysis, 
CD8 mRNA was practically undetectable at time zero and increased >4-fold by 6h 
compared to IL-2 alone, demonstrating that TGFp was indeed effecting de novo CD8 
expression in CTLL-2 and not merely favoring outgrowth of CD8+ cells. 
When changes in the steady-state level of a specific mRNA are seen during 
Northern analysis, it is formally possible that transcriptional and/or post-transcriptional 
mechanisms account for these changes. Preliminary in vitro nuclear run-on assays 
have shown no increase in the rate of CD8a transcription after treatment of CTLL-2 
with TGFp. Further work is necessary to identify the precise mechanism by which IL-
2 and TGFp increase CD8a mRNA levels. Whatever the mechanism, it is clear that 
the metabolism of CD8 mRNA is changed in TGFp-treated cells  as evidenced by the 
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dramatic enhancement (>50-fold in 24h) of CD8u mRNA level upon re-addition of 
fresh IL-2 + TGF� 48h after the initial treatment with IL-2 + TGF�. Mechanistically, 
one could speculate that the primary (time zero) addition of TGF� resulted in the 
production of stable transcriptional components that were, at 48h still poised to 
continue rapid synthesis of CD8u mRNA in response to fresh IL-2 and TGF�. It is 
also formally possible that the enhanced response to TGF� 48h after primary treatment 
with TGF� results from an increase in the number or afftnity of cell surface receptors 
for TGF�, thus resulting in a quantitatively or qualitatively stronger signal upon 
secondary addition. In any event, it is interesting that no greater number of CD8+ cells 
emerged after secondary treatment with IL-2 + TGF�, nor did the level of CD8 
antigen increase on a per cell basis when MFI values were compared before and after 
re-addition, suggesting that in this model, CD8u surface expression may be regulated 
post-transcriptionally, as has been reported for CD8� (Parnes, 1 989). 
TGF{3 affects cytoskeletal components and adhesion receptors 
Treatment of CTLL-2 cells with TGF� resulted in a striking change in morphol­
ogy, causing these cells to become spindle-shaped or stellate and causing a large 
percentage of cells to adhere to the culture plate. The expression of several molecules 
(CD44, LFA- l ,  and ICAM- I )  known to be involved in the interaction of lymphocytes 
with the extracellular matrix were examined and shown to be minimally affected in by 
TGF� in this CTLL-2 model. Further efforts are underway to ascertain the identity of 
the molecules involved in adherence in TGF�-treated cultures. Stoeck, et al. also 
described changes that occurred in the microscopic appearance of their CTLL-2 line 
after treatment with TGF�, but noted that the cells became more clustered, ie. adherent 
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to each other, rather than to the plate (Stoeck et aI . ,  1 989a). Nonetheless, it is likely 
that these two observations are secondary to similar changes that are triggered by 
TGFI) in CTLL-2 cells. T lymphocytes can attach to protein-coated tissue culture 
plates via surface integrin molecules (Utsumi et aI . ,  1 99 1 ), and it is known that TGFI) 
can cause up-regulation of multiple components of the integrin family of adhesion 
molecules, can modulate extracellular matrix organization, and enhance the attachment 
of thymocytes to a fibronectin substratum (Heino et aI . ,  1 989; Ignotz et aI. ,  1 989; 
Merwin et aI. ,  1 990; Ignotz and Massague, 1 987). Therefore, the expression of an 
adherent phenotype in CTLL-2 and the antagonism of this adherence with RGDS 
peptide essentially confirms the premise that TGFI) up-regulates integrin I) chains on T 
cells. Further, the presence of TGFI) in thymus tissue sections (Ellingsworth et aI . ,  
1 986) allows the speculation that this cytokine may be  involved in  adherence of  
differentiating thymocytes to the selecting epithelium. 
In several experiments presented in Chapter 2, it appeared that increases in I)-actin 
mRNA level were seen in CTLL-2 treated with TGFI). These increases were seen at 
the same timepoints when TGFI) inhibited accumulation of other mRNA species, and 
ethidium stained rRNA revealed little gross difference in total RNA loaded. In this 
chapter, TGFI)-dose response Northern analyses were performed which clearly showed 
that CTLL-2 accumulated I)-actin mRNA in a TGFI)-dose dependent manner. It was 
previously shown that TGFI) induces cytoskeletal changes in epithelial cell lines (Garbi 
et al . ,  1 990) and some of these changes have involved TGFI)-dependent increases in 
actin polymerization (Lomri and Marie, 1 992). Further, it was demonstrated that 
TGFI) elevates steady-state I)-actin mRNA levels (but without effect on mRNA coding 
for glyceraldehyde-6-phosphate dehydrogenase) in epithelial cell lines (Suemori et aI . ,  
1 2 1  
1 99 1 )  and i n  cardiac fibroblasts (Eghbali et aI., 1 99 1 )  and synergises with epidermal 
growth factor for increasing the rate of transcription of p-actin in AKR fibroblasts 
(Ranganathan and Getz, 1 990). Thus, our data suggest that T lymphocyte p-actin is 
also a target of TGFp action which may be causally related to the microscopic changes 
seen in CTLL-2 morphology. 
TGF{3 receptor signalling 
The serine and threonine specific protein kinase-C (PKC) is involved in TCR 
signalling (Rao, 1 99 1 ; Albert et aI . ,  1 985;  Valge et aI . ,  1 988), but is not required for 
signalling through the IL-2R (Tigges et aI . ,  1 989; Mills et aI . ,  1 988;  Valge et aI . ,  
1 988) .  As neither viability or growth of CTLL-2 cells requires TCR signals and since 
IL-2 signalling is independent of PKC activation, CTLL-2 cells represent a suitable 
model to study the role of PKC in TGFp-induced CD8 expression. Our results 
showed that when CTLL-2 were depleted of PKC by continuous exposure to high-dose 
PDBu, only 50-60% of cells became CD8+, even when challenged with 5ng/ml of 
TGFp. Since treatment of CTLL-2 with PDBu does not interfere with IL-2-induced 
proliferation (data not shown), these data suggest that PKC participates in TGFp 
receptor signalling in CTLL-2. These data are congruent with results obtained in 
epithelial cell lines where it was found that although TGFp responses could be blocked 
by serine/threonine kinase inhibitors H7 and H8, treatment with PKC-specific 
staurosporine or depletion of PKC with high-dose PMA was without effect on TGFp 
responses (Ohtsuki and Massague, 1 992) . 
Cytokine regulation of thymocyte ontogeny 
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Intrathymic T cell differentiation undoubtably involves complex interrelationships 
between stromal elements in the thymic microenvironment (Van Ewijk, 1 99 1 ) . It is 
also clear that cytokines such as IL- 1 through IL-7, CSFs, TNF-a, IFN-y, TGF-a and 
-P play important roles in T cell ontogeny (Carding et aI., 1 99 1 ), although precise 
cause and effect relationships between the various cytokines and T cell differentiation 
processes are unclear. Many studies (including those described herein) of T cell devel­
opment must then be interpreted with caution, since the major shortcoming of cell 
differentiation models is that they often cannot accurately replicate microenvironmental 
conditions that are present in vivo. 
Thymic lymphocytes are a heterogeneous population of cells; distinct 
subpopulations of thymocytes, each having its own microheterogeneity have been 
noted (MacDonald et aI . ,  1 988) and the small size of some of these subpopulations 
have limited extensive investigation of functional potential . Herein, we have 
demonstrated that when unseparated thymocytes are briefly incubated with an activator 
of protein kinase C and a calcium ionophore and subsequently cultured in IL-2, TGFp 
treatment causes higher percentages of CD8a+ cells to emerge. On average, these cells 
also exhibited higher surface densities of CD8a and CD8P antigens as compared to 
controls, while CD4 expression was unaltered by TGFp treatment. Since elevated 
CD8 mRN A levels were seen at 1 8  and 48h after TGFp addition, it is likely that 
TGFp is effecting de novo expression of surface CD8 on these thymocytes rather than 
promoting passive acquisition of the CD8 antigen from other cells, as described by 
others (Shores et aI . ,  1 99 1 ) . 
The most immature thymocytes are contained in the DN subpopulation. In this 
system, treatment of DN thymocytes with IL-2 + TGFp induced progressively higher 
levels of CDS surface density in 30% of cells, whereas IL-2 or TGFp alone was an 
insufficient stimulus for CDS expression. Although DN thymocyte growth was 
inhibited by TGFp, approximately a 240-fold increase in the number of CDS+ cells 
1 23 
was observed during 4 days in culture. Thus, this culture system may be valuable for 
investigating CDS precursor potentials in populations that have low starting cell 
numbers, such as subsets of DN thymocytes. Most of the CDS+ cells that emerged 
from the DN population were immature, Thy l +TCRJCD3-CD4-CDS\ thus providing 
further evidence for the existence of such cells as a discrete phenotypic stage in 
thymocyte development. These data also implicate TGFp as a possible mediator of the 
transition from the DN to the immature CDS SP stage, which is thought to precede the 
DP stage of development (Nikolic-Zugic et aI . ,  1 9S9). During these studies, cells with 
a more mature phenotype did not emerge, even after prolonged culture in IL-2 or IL-2 
+ TGFp. Perhaps additional cytokine(s) and/or cell-to-cell contact between 
lymphocytes and stromal cells are required for CD4 expression in immature 
thymocytes. In this regard, co-culture of DN thymocytes with a thymic stromal cell 
clone (MRL 1 04.Sa), or a semi-purified T cell growth factor released from these cells, 
resulted in the emergence of a small subpopulation ( 1 0-20%) of CD3-CD4-CDS+ cells 
(Tatsumi et aI . ,  1 990; Nagamine et aI . ,  1 99 1 ). Interestingly, DP cells emerged only 
after prolonged co-culture with the MRL 1 04.Sa monolayer but not after treatment with 
the supernatant factor alone (Tatsumi et aI . ,  1 990). There is currently little infor­
mation available regarding the exact identity of cytokines that are required for 
intrathymic T cell maturation processes. 
There are abundant data implicating TGFp as a regulatory molecule in cellular 
differentiation processes. TGFp inhibits differentiation of pre-adipocytes (Ignotz and 
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Massague, 1 985), myoblasts (Massague et al . ,  1 986; Olson et ai . ,  1 986), and inhibits 
the terminal differentiation of CTL precursors into CTL effectors (Ranges et ai . ,  1 987; 
Fontana et ai., 1 989;  Shalaby and Amman, 1 988;  Wallick et ai ., 1 990; Tada et ai ., 
1 99 1 ). Conversely, there are numerous reports that TGFp stimulates differentiation of 
epithelial and certain mesodermal cells (Seyedin et ai., 1 986; Seyedin et ai . ,  1 987;  
Potts and Runyan, 1 989; Kurokowa et ai . ,  1 987). Our results further suggest that 
TGFp may be a positive regulator of early differentiation-related events in immature T 
cells and are in agreement with recent reports by Suda and Zlotnick demonstrating that 
TGFp as well as TNFa stimulate CD8 expression in normal, CD3-CD4-CD8-CD25+ 
thymocytes (Suda and Zlotnik, 1 992a; Suda and Zlotnik, 1 992b). TGFp mRNA is 
expressed in the thymus during murine embryogenesis (Millan et ai., 1 99 1 )  and 
immunohistochemical analysis of bovine thymus has shown that TGFp can be detected 
in Hassall ' s  corpuscles and in medullary reticuloepithelial cells--anatomic sites thought 
to be involved in critical steps of T cell differentiation and selection--but not in 
thymocytes, cortical accessory cells, or thymic capsule (Ellingsworth et ai . ,  1 986). 
Despite a large body of knowledge regarding the regulation of expression of TCR 
components during thymocyte ontogeny (Clevers and Owen, 1 99 1 ), very little is 
known about the physiologic signals and genetic regulatory mechanisms that result in 
initial CD8 expression in T lymphocytes. This area has not been fully explored 
largely due to the lack of suitable models in which CD8 expression can be manipulat­
ed. The fact that both CTLL-2 and normal immature thymocytes show enhanced de 
novo expression of CD8 chains in response to IL-2 and TGFp indicates that these will 
be useful models to study the molecular regulation of CD8 expression, and supports 
the hypothesis that these cytokines may be important immunoregulatory factors during 
the differentiation of normal T lymphocytes. 
TGF{3: Physiological regulator of T lymphocyte proliferation and memory T 
lymphocyte production? 
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It is known that T cell expansion after activation is tightly regulated in a paracrine 
and/or autocrine fashion by the production of IL-2 and the expression of IL-2R. 
However, the factors regulating two other important processes that occur after T cells 
are clonally expanded remains elusive: restoration of the state of IL-2 unresponsive­
ness and long-term survival of the subset of T cells that has proven the value of its 
particular TCR paratope (memory induction). TGFp may be pivotal in this sense. In 
response to antigenlMHC in the context of APC-derived costimulating factors, antigen 
specific clones of Th cells become activated and begin to produce a battery of 
cytokines to "help" the proliferation and functional differentiation of pre-effector CD8 
T lymphocytes. Among these cytokines are IL-2 and IL-4, which are responsible for 
the well characterized autocrine proliferative loop. TGFp may be also involved in a 
parallel autocrine loop, one which may function to both counteract (in terms of 
proliferation) and alter cellular differentiation programs in the presence of other 
cytokines such as IL-2 and TNFa. Th cells synthesize TGFp mRNA within several 
hours of being activated, however the protein product is not secreted until days 
afterward (Kehrl et al . ,  1 986b). Coincident with the general timeframe of TGFp 
production (5-7 days post activation), effector T cells that had been IL-2 responsive 
and proliferative for several days become IL-2 resistant (Gull berg and Smith, 1 986). 
This IL-2 resistant state is characterized by the inability of the cells to grow in 
response to exogenous IL-2 even though IL-2Ra levels may remain high; this condi-
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tion is mirrored by functional CTL clones in vitro (Figures 1 .03 and 1 .04). Interest-
ingly, it was recently shown that this IL-2 resistant phenotype was lost in T cell clones 
that had lost TGF� receptors (Siepl et ai . ,  1 99 1 ) . The observed antiproliferative effect 
of exogenous TGF� on T cells supports the hypothesis that TGF� is a factor which 
could account for the phenomenon of IL-2 resistance that occurs in the ensuing days 
after antigenic stimulation, and further predicts that TGF� that is produced 
physiologically in T cell microenvironments may modulate I L-2 responsiveness. 
There are now several lines evidence implicating TGF� in alteration of T cell 
differentiation programs. We and others have shown that TGF� stimulates 
differentiation of thymocytes of the CD8 lineage (lnge et ai . ,  1 992c; Suda and Zlotnik, 
1 992a), but TGF� also affects expression of other differentiation markers. When 
normal T cell are treated with exogenous TGF� a high percentage of cells begin to 
express isoforms of CD45 that are characteristic of memory T cells (Swain et ai . ,  
1 99 1 ) . T cells treated with TGF� have been shown to more aggressively engage 
antigenic stimuli in an encephalitis model, again suggesting that TGF� may be 
important for the development of memory T cells (Weinberg et ai . ,  1 992). Thus, some 
of the observed effects of TGF� on T cells make it a good candidate to explain some 
of the yet poorly understood phenomena that occur in the life of a T lymphocyte. 
Future work will surely elucidate complex relationships between the many cytokines 
that together regulate T cell differentiation, T -dependent immune responses, and ensure 
the survival of relevant clones for future reactivation. In summary, this information 
supports the hypothesis that TGF� plays a key role in T lymphocyte homeostasis, 
participating in the regulation of cellular differentiation, proliferation, and memory 
induction. 
Table 3 .0 1 : CD8 surface expression requires new RNA synthesis 
IL-2 
IL-2 + TGFI) 
IL-2 + TGFI) + Act-D 
Expt # 1  
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Table 3.02: PKC activation does not substitute for TGFp signal 
Percent CD8+ Cells 
Tx funtl � 
IL-2 1 8  4 
IL-2 + TGF.B 33 12 
1L-2 + 1 00nM PDBu 6 3 
1L-2 + 1,000nM PDBu 8 3 
1L-2 + 1O-6M 10 4 
1L-2 + 100nM PDBu + 10 2 
1 29 
Table 3 .03 : Effect of PKC depletion on CD8 expression 
Incubate 48h in: Wash, then another 24h in: %CD8+ 
Expt: # 1  #2 
IL-2 IL-2 4 3 
IL-2 + TGF� ( I nglml) 25 1 8  
IL-2 + TGF� (5ng/ml) 1 8  
IL-2 + PDBu IL-2 7 1 
IL-2 + TGF� ( l nglml) 1 6  1 0  
IL-2 + TGF� (5ng/ml) 1 0  
IL-2 + PDBu 5 1 
IL-2 + PDBu + TGF� ( l ng/ml) 1 3  6 
IL-2 + PDBu + TGF� (5ng/ml) 7 
Concentrations used: IL-2, 20U/ml; PDBu, I IlM 
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Table 3 .04:  CD8 expression in mature, peripheral T cells 
ResI1onder" Stimb TGF[3 Pheno!YI1e LysisC 
CD4 CD8 1 0 :  1 5 :  1 
% MFI % MFI 
TBH spleen 66 1 1 5 24 77 2 2 
TBH spleen + 52 1 1 6 26 77 44 33  
TBH spleen + 2.5 49 1 05 23 73 26 1 5  
TBH spleen + 5 45 1 08 25 75 23 1 5  
a Splenocytes were obtained from early tumor bearing hosts (TBH, day 1 2  after i .d. 
inoculation of PHS-5 tumor cells 
b Stimulator (Stirn) cells were P8 1 5  cells treated with mitomycin-C 
C Lysis refers to % specific lysis of 5 1Cr labelled P8 1 5  target cells 
Table 3 .05 :  CD8a expression in TGF�-treated double negative thymocytes 
% CD8a+ Cells CMF!) 
Exp 1 Exp 2 Exp 3" 
Day 4 
IL-2 7 (23) 7 (38) 1 2  (29 1 )  
IL-2+TGF� 32 (22) 36 (50) 3 1  (506) 
Day 6 (or 8) 
IL-2 7 (23) 1 1  (38)b 1 0  (490) 
IL-2+TGF� 26 (49) 48 (53)b 29 (7 1 6) 
a Cells from experiment 3 were stained with a phycoerythrin-conjugated anti-CD8a, 
resulting in higher MFI values than in experiments 1 and 2, where FITC-conjugates 
were used 
b Immunofluorescence perfonned on day 8 
l 3 1  
Table 3 .06: Proliferation of CD8+ and CD8' subpopulations of TGFf3-treated DN 
thymocytes 
Mean 3H_ Thymidine Incorporation in cpm (SD) 
CD8' 
25,788 (3,582), 
55 , 1 67 (3 ,059) 
IL-2+TGFB 
1 9,646 (2,280)b 
24,805 (3,556)" 
a p<O.OOI compared to CD8' cells in IL-2 alone by Students' t-test 
b p<0.03 compared to CD8+ cells in IL-2 alone 
1 32 
C p>0.05 compared to CD8+ cells in IL-2 + TGFf3; p<O.OOO I compared to CD8' cells in 
IL-2 alone 
1 33 
Figure 3 .0 1 : Photomicrograph of TGF�-treated CTLL-2. CTLL-2 were cultured in 
24-well tissue culture plates in 20U/ml IL-2 in the absence (panel A) or presence 
(panel B) of l ng/ml TGF� for 2 days prior to phase contrast photomicroscopy. Bar 
length is 1 001lm. 
134 
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Figure 3 .02 : Morphologic characteristics o f  CTLL-2 by FACS analysis. CTLL-2 
were treated with 20U/ml IL-2 ± I ng/ml TGFp for 24h prior to measurement of 
forward angle (FSC, left panel) and side angle (SSC, right panel) light scattering 
characteristics. Light scatter is shown along the abscissa, and cell number along the 
ordinate. 
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Figure 3 .03 : CTLL-2 adhere to culture plate after TGF� treatment. A) Experiment 
# I ;  B) Experiment #2. In each experiment, CTLL-2 were cultured at 5x I 04 cells/well 
in duplicate 96-well plates with 20ulml IL-2 and various concentrations of TGF�. 
After 24h, one plate was filled with medium, inverted, and centrifuged as described in 
Materials and Methods. Adherent cell mass was then measured by MTT, and cell 
numbers calculated by comparison of optical density values to a standard curve. Cells 
in the duplicate plate were not centrifuged, but were similarly stained with MTT to 
obtain "total" cell numbers. 
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Figure 3 .04 : Maximal adherence occurs at 24h. CTLL-2 were cultured for various 
periods of time in 20U/ml IL-2 ± 1 or Sng/rnl TGFp. Adherence was measured as 
described in Figure 3 .03 and in Materials and methods. 























� l  !--!�6, 
1 40 
6,-6, IL-2 
. - .  IL-2+TGFp ( 1 ng/mt) 
+ - +  IL-2+TGFp (5ng/ml) 
/' � ===- I �6, __ -O �--�---+--�--�r-��--�--�---; 
o 3 6 1 2  24 48 
Time (h) 
1 4 1  
Figure 3 .05 :  FCS i s  required for adherence. CTLL-2 were cultured i n  DMEM 
without fetal calf serum (FCS) with IL-2 + 5ng/ml TGFp for 24h prior to adherence 
assay. The following soluble ingredients were added to groups as designated along the 
abscissa: fetal calf serum (FCS) at various % concentrations (vol/vol) bovine serum 
albumin (BSA) at 1 %  (wtlvol), rat tail collagen type I (COLL) at 1 OIlg/ml, or bovine 
serum fibronectin (FN) at 1 0  or 50Ilg/ml. Simultaneous assay of groups treated with 
IL-2 without TGFp (data not shown) demonstrated that the high background adherence 
in Expt # 1  in the absence of FCS was equivalent between the groups, and therefore 
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Figure 3 .06: RGDS peptide blocks adherence. CTLL-2 were treated with 20U/ml IL-
2 + Snglml TGFp in medium containing various concentrations of FCS and 
tetrapeptides. RGDS (Arg-Gly-Asp-Ser) was added at I OIlg/ml (Experiment # 1 )  or 
SOllg/ml (Experiment #2). Control tetrapeptide RGES (Arg-Gly-Glu-Ser) was added at 
SOllg/ml. 








1 0  
o 












Figure 3 .07: Surface phenotype of TGF�-treated CTLL-2. CTLL-2 were cultured for 
two days (A) or one day (B) in 20U/ml IL-2 alone (left) or IL-2 + I ng/ml TGF� 
(right) prior to immunofluorescence analysis. Fluorescence intensity (abscissa) was 
quantitated by flow cytometry using four decade log amplification. These data are 
representative of 3 separate experiments. In panel A, CD8 was detected with PE­











IL·2 + TGFI3 
IL-2 
IL-2 + TGF8 
1 47 
Figure 3 .08 :  CD8 expression in adherent and non-adherent CTLL-2. CTLL-2 were 
cultured for 48h in DMEM + 1 0% fetal calf serum + 20U/ml IL-2 + l ng/ml TGF� in 
24-well plates. Non-adherent cells (NonAdh) were harvested by gently piperting, 
while adherent (Adh) cells required vigorous piperting with ice-cold media for efficient 
harvest. Plots are shown for isotype control staining (Control) and TGF�-treated cells 
stained for CD8u. 
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Figure 3 .09: CD8 expression is uniform throughout the population. CTLL-2 were 
treated for 24h with 20u/ml IL-2 + I ng/ml TGF� prior to staining for CD8u. Fluores­
cence data were then displayed as follows: A) CD8u immunofluorescence (abscissa) 
as a function of cell number (ordinate) ;  B) contour plot of CD8u (ordinate) as a 
function of forward angle light scatter (FSC, abscissa); C) contour plot of CD8u 
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Figure 3 . 1 0: Coordinate analysis of CD8a and other markers. CTLL-2 cells were 
treated for 24h with 20U/ml IL-2 + I ng/ml TGF�. Cells were stained with PE­
conjugated CD8a (ordinate) and either no additional stain (panel A), or the following 
FITC-conjugated Ab: B) IL-2Ra, C) LF A- I ,  D) CD8�, E) Thy- I ,  F) ICAM- I .  






Figure 3 . 1 1 :  Coordinate expression of CD8u and CD8p. CTLL-2 were treated with 
IL-2 alone or IL-2 + various concentrations of TGFp. After 1 day, cells were 
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Figure 3 . 1 2 :  Kinetics of CD8a expression on TGF�-treated CTLL-2. CTLL-2 were 
treated with 1L-2 ± 1 ng/ml TGF� and CD8a chain was analyzed over time. Multiple 
experiments were pooled to obtain mean %CD8+ values ± SEM. The number of 
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Figure 3 . 1 3 :  Kinetics of CD8� expression on TGF�-treated CTLL-2. CTLL-2 were 
treated with IL-2 ± I ng/ml TGF� and CD8� chain expression was analyzed over time. 
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Figure 3 . 1 4 : Inhibition of CTLL-2 proliferation with hydroxyurea. CTLL-2 were 
treated with medium alone, 20U/ml IL-2, or IL-2 + various concentrations of hydroxy­
urea (HU). Thirty seven kBq of 3H-thymidine was added at initiation of cultures and 
incorporation was measured 24h later. Points represent the arithmetic mean cpm (± 
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Figure 3 . 1 5 : Stability of CD8u expression after TGF� washout. CTLL-2 were treated 
with IL-2 + 1 ng/ml TGF�. One day later, cultures were harvested and washed prior to 
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Figure 3 . 1 6 : Stability of CDSa expression after subset enrichment. CTLL-2 were 
treated with IL-2 + I ng/ml TGFp on days 0 and 2. On day 3 ,  panning was performed 
to separate CDS+ from CDS' cells, and each subset was then cultured in IL-2 ± TGFp. 
On days 2, 5 ,  and S thereafter, CDS immunofluorescence was determined. These data 
are representative of 2 separate experiments. 
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Figure 3 . 1 7 : Northern analysis of TGFp-treated CTLL-2. CTLL-2 were cultured for 
various periods in 20U/ml IL-2 ± I ng/ml TGFp prior to Northern analysis of CD8u 
and p-actin. 
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Figure 3 . 1 8 : Northern analysis of TGF�-treated CTLL-2. CTLL-2 were cultured for 
0, 3, 6, 1 2, or 24h with 20U/ml IL-2 in the absence ("-") or presence ( "+") of I ng/ml 
TGF� prior to analysis of mRNA. 
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Figure 3 . 1 9 :  Secondary response of CD8u mRNA after TGF� treatment. A) CTLL-2 
were cultured for various periods in 20U/ml IL-2 ± I ng/ml TGF� prior to Northern 
analysis of CD8u. B) Rehybridization of blot from experiment 3 with �-actin probe. 
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F igure 3 .20:  TGF�-dose response Northern analysis of CD8.  CTLL-2 were treated 
with 20U/ml IL-2 ± various concentrations of TGF� for 24h prior to Northern analysis 
of CD8a and CD8�. After probing for CD8, the blot was stripped and repro bed for 
�-actin. Data shown represent relative signal intensities as measured by densitometric 
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Figure 3 .2 1 :  CTLL-2 cytolytic activity. CTLL-2 and control tumor-specific CTL 
were treated with 20U/ml IL-2 ± l ng/ml TGF� for 2 days prior to cytotoxicity assay 
against 5 lCr-labelled PHS-S or F4S tumor cells. "PHS-S Specific CTL" was a control 
CTL line generated by repeated rounds of in vitro sensitization culture against the 
PHS-S mastocytoma as described (McKinnon et aI . ,  1 990). "TGF�" along the abscissa 
of this graph refers to the presence or absence of this cytokine during the 2d culture 
period prior to assay. "2C l l "  along the abscissa refers to the presence or absence of 
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Figure 3 .22:  TGFp does not affect CD8 expression in ML TC. ML TC established 
with splenocytes from day 1 0  P8 1 5-tumor bearing mice were either: A) unstimulted = 
cultured in media alone; B) stimulated = cultured with mitomycin-C-treated PHS-5 
cells; C) stimulated + 2 .5ng/ml TGFp added at initiation of culture; or D) stimulated + 
5ng/ml TGFp added at initiation of culture. After six days of culture, CD8u expres­
sion was ascertained by FACS. See Table 3 .04 for numerical analysis of FACS data 




Figure 3 .23 :  TGFp inhibits thymocyte proliferation. Thymocytes were stimulated 
overnight with PDBu + 10 and cultured with 20U/ml IL-2 ± I ng/ml TGFp. At various 
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Figure 3 .24: FACS analysis of CD8u and CD4 or CD8 P  on normal thymocytes. 
Panel A. Fresh DBAl2 thymocytes. Panel B. Thymocytes stimulated overnight with 
PDBu + 10 and cultured for 4 days with 20U/ml IL-2 alone. Panel C. Thymocytes 
stimulated overnight with PDBu + 10 and cultured for 4 days with 20U/ml IL-2 + 
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Figure 3 .25 :  Northern analysis of TGF�-treated thymocytes. DBN2 thymocytes were 
stimulated overnight with PDBu + 10 + 20Ulml IL-2, then cultured for 2 additional 
days in 20U/ml IL-2. On day 3, cells were washed and re-cultured in either medium 
alone, 20U/ml IL-2, I ng/ml TGF�, or IL-2 + TGF� for 1 8  or 48h prior to Northern 
analysis of CD8u. For cells that did not receive IL-2, (lanes 1 & 3) viability rapidly 
decreased after 1 8h, and were thus not analyzed at 48h. Despite equal loading of 
RNA by ethidium bromide staining, cells cultured without IL-2 also demonstrated 
lower levels of �-actin mRNA, congruent with the fact that most of these cells were 
dead after 24h of IL-2 deprivation. Comparison of �-actin signals between groups that 
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Figure 3 .26: CD4 and CD8 expression on cultured DN thymocytes. DN thymocytes 
were cultured in 20U/ml IL-2 alone (upper panel) or IL-2 + I ng/ml TGF� (lower 
panel) and stained on days 2, 4, and 6 with anti-CD8a and anti-CD4. These data are 
representative of 5 separate experiments. 
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Figure 3 .27: TCR expression on TGF�-treated DN thymocytes. DN thymocytes were 
cultured in 20U/ml IL-2 alone (upper panel) or IL-2 + l ng/ml TGF� (lower panel) and 
analyzed on day 4 for surface expression of Thy l ,  a�-TCR, or gamma delta-TCR as a 
function of CD8a immunofluorescence. 
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